Structural and biochemical characterization of marburgvirus VP35 and its role in immune evasion by Ramanan, Parameshwaran
Graduate Theses and Dissertations Iowa State University Capstones, Theses andDissertations
2012
Structural and biochemical characterization of
marburgvirus VP35 and its role in immune evasion
Parameshwaran Ramanan
Iowa State University
Follow this and additional works at: https://lib.dr.iastate.edu/etd
Part of the Biochemistry Commons
This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University
Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University
Digital Repository. For more information, please contact digirep@iastate.edu.
Recommended Citation
Ramanan, Parameshwaran, "Structural and biochemical characterization of marburgvirus VP35 and its role in immune evasion"
(2012). Graduate Theses and Dissertations. 12889.
https://lib.dr.iastate.edu/etd/12889
Structural and biochemical characterization of marburgvirus VP35 and its role in 
immune evasion 
 
by 
 
Parameshwaran Ramanan 
 
A thesis submitted to the graduate faculty 
in partial fulfillment of the requirements for the degree of 
DOCTOR OF PHILOSOPHY 
 
 
Major:  Biochemistry 
 
Program of Study Committee: 
 
Gaya K. Amarasinghe, Co-major Professor 
Richard B. Honzatko, Co-major Professor 
Michael Shogren-Knaak 
Mark S. Hargrove 
Drena L. Dobbs 
 
 
Iowa State University 
Ames, Iowa 
2012 
Copyright © Parameshwaran Ramanan, 2012.  All rights reserved. 
 ii 
 
 
TABLE OF CONTENTS 
 
LIST OF FIGURES v	  
LIST OF TABLES vii	  
LIST OF ABBREVIATIONS viii	  
ABSTRACT xi	  
CHAPTER 1. HOST INNATE IMMUNITY 1	  
1.1 Introduction 1	  
1.2 Pattern recognition receptors 3	  
1.3 Toll-like receptor signaling 4	  
1.4 C-type lectin receptor signaling 10	  
1.5 NOD-like receptor signaling 15	  
1.6 RIG-I-like receptor signaling 19	  
1.7 Type I IFN signaling pathway 25	  
1.8 Viral inhibitors of innate immune responses 26	  
1.9 Conclusions 31	  
1.10 References 32	  
CHAPTER 2. FILOVIRUSES OVERVIEW 42	  
2.1 Introduction 42	  
2.2 Filovirus pathogenesis 43	  
 iii 
 
2.3 Filovirus replication cycle 44	  
2.4 Differences between ebolavirus and marburgvirus 63	  
2.5 Conclusions 65	  
2.6 References 67	  
CHAPTER 3. STRUCTURAL BASIS FOR IMMUNE EVASION BY EBOLA VP35 75	  
3.1 Introduction 76	  
3.2 Materials and methods 77	  
3.3 Structure of EBOV VP35 IID-dsRNA complex 79	  
3.4 CBP residues are involved in VP35-VP35 and VP35-dsRNA interactions 81	  
3.5 ZEBOV VP35 dsRNA binding is correlated with IFN inhibition in vivo 87	  
3.6 Mutation of CBP residues renders recombinant ZEBOV avirulent in  
      guinea pigs 89	  
3.7 Conclusions 92	  
3.8. References 96	  
CHAPTER 4. STRUCTURAL BASIS FOR MARBURG VIRUS VP35  
                       MEDIATED IMMUNE EVASION MECHANISMS 98	  
4.1 Introduction 99	  
4.2 Materials and methods 100	  
4.3 Biochemical comparison of ebolavirus and marburgvirus  
      C-terminal domain 104	  
4.4 Structural studies of filoviral VP35 reveals distinct RNA binding modes 109	  
4.5 Filoviral VP35 differentially inhibits RIG-I and MDA5 ATPase activity 123	  
 iv 
 
4.6 Disruption of VP35-dsRNA interactions in vitro results in attenuated  
      IFN  inhibition in vivo 127	  
4.7 Conclusions 131	  
4.8. References 135	  
CHAPTER 5. CONCLUSIONS 137	  
ACKNOWLEDGEMENTS 140	  
 
 v 
 
LIST OF FIGURES 
Figure 1-2. Structural basis for dsRNA recognition by TLR3.    8 
Figure 1-3. Structural basis for carbohydrate recognition by CLRs.    12 
Figure 1-4. CLR mediated signaling.        14 
Figure 1-5. Structure of the ligand binding domain of NOD-like receptor.   16 
Figure 1-6. NLR mediated signaling.        18 
Figure 1-7. Structure of autoinhibited and dsRNA-bound RIG-I.    21 
Figure 1-8. RLR mediated signaling.        24 
Figure 1-9. IFN mediated signaling.        27 
Figure 2-1. Filoviral genome organization.       46 
Figure 2-2. Structure of filoviral GP protein.       48 
Figure 2-3. Filoviral replication cycle.       50 
Figure 2-4. Crystal structures of EBOV VP40.      54 
Figure 2-5. Crystal structures of EBOV VP24.      56 
Figure 2-6. Crystal structure of EBOV VP30.      58 
Figure 2-7. Crystal structures of EBOV VP35 IID.      60 
Figure 2-8. Functionally important residues in ZEBOV VP35 IID.    62 
Figure 3-1. Structure of ZEBOV VP35 IID in complex with 8bp dsRNA.   80 
Figure 3-2. CBP residues are important for VP35-VP35 and VP35-dsRNA interactions.    82 
Figure 3-3. VP35 IID caps the blunt-ends of dsRNA.     83 
Figure 3-4. Structure of CBP mutants of ZEBOV VP35 IID.    84 
Figure 3-5. ZEBOV VP35 IID competes with RIG-I for dsRNA binding.   86 
 vi 
 
Figure 3-6. dsRNA binding and IFN inhibition are correlated.    88 
Figure 3-7. Replication of recombinant ZEBOV with CBP mutations  
                   is attenuated in 293T cells.       90 
Figure 3-8. Recombinant ZEBOV VP35 IID with CBP mutations is  
                   avirulent in guinea pigs.                   91 
Figure 3-9. Mechanisms of EBOV proteins inhibition of host immune responses.             95 
Figure 4-1. Multiple sequence alignment IID region of filoviral VP35 proteins.             106 
Figure 4-2. Identification of MARV VP35 IID domain boundary by NMR.              108 
Figure 4-3. MARV VP35 IID binds to dsRNA in a length dependent manner.             110 
Figure 4-4. Crystallization of MARV VP35 IID-dsRNA complex.               112 
Figure 4-5. Crystal structure of MARV VP35 IID bound to 18bp dsRNA.              115 
Figure 4-6. Residues involved in dsRNA binding in MARV VP35 IID.              116 
Figure 4-7. Residues involved in protein-protein interactions in MARV VP35 IID.            117 
Figure 4-8. Mutation of residues involved in mediating dsRNA contacts in structure  
                   also diminish dsRNA binding in vitro.                 119 
Figure 4-9. Overall fold of MARV VP35 IID is conserved and similar to EBOV.             120 
Figure 4-11. MARV VP35 IID is insensitive to overhangs in dsRNA, unlike EBOV.         122 
Figure 4-12. MARV VP35 IID cannot inhibit dsRNA activation of RIG-I.              124 
Figure 4-13. MARV VP35 is able to inhibit activation of MDA5 by poly I:C.             126 
Figure 4-14.  Mutations of residues involved in dsRNA binding in MARV VP35 IID  
                      attenuate IFN- β inhibition and IRF-3 phosphorylation.   128 
Figure 4-15.  RNA-independent mechanism of immune evasion by MARV VP35.             130 
Figure 4-16.  Model for filoviral VP35 mediated immune evasion.               134 
 vii 
 
LIST OF TABLES 
Table 4-1. Statistics for data collection and refinement for MARV VP35 IID-dsRNA 
                 complex.          113 
Table 4-2. Biochemical and structural differences between MARV and EBOV VP35  
                  proteins, which are important for immune evasion mechanisms.  133 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 viii 
 
LIST OF ABBREVIATIONS 
Activator protein-1 AP-1 
Antigen presenting cell APC 
Baculovirus inhibitor of apoptosis protein repeat domain BIR 
C-type lectin receptor CLR 
Carbohydrate recognition domain CRD 
Caspase activation and recruitment domain CARD 
Central basic patch CBP 
DC-associated C-type lectin DECTIN 
DC-specific ICAM3-grabbing nonintegrin DC-SIGN 
Death domain DD 
Dendritic cell DC 
Double-stranded RNA dsRNA 
double-stranded RNA binding domain dsRBD 
dsRNA dependent protein kinase PKR 
Ebolavirus EBOV 
Endosomal sorting complex required for transport ESCRT 
First basic patch FBP 
Heteronuclear single quantum coherence HSQC 
Iκβ kinase IKK 
Immunoreceptor tyrosin-based activation motif ITAM 
In-vitro transcription IVT 
Interferon IFN 
Interferon inhibitory domain IID 
 ix 
 
Interferon regulatory factor IRF 
Interferon stimulated gene ISG 
Interleukin-1 receptor associated kinase IRAK 
Isothermal titration calorimetry ITC 
Laboratory of genetics and physiology 2 LGP2 
Leucine-rich repeat LRR 
Lipopolysaccharide LPS 
Macrophage mannose receptor MMR 
Macrophage-inducible C-type lectin MINCLE 
Marburgvirus MARV 
Melanoma differentiation associated gene 5 MDA5 
Mitogen activated protein kinase MAPK 
Myeloid C-type lectin-like receptor MICL 
Natural killer cell NKC 
Neuronal apoptosis inhibitory protein NAIP 
Newcastle disease virus NDV 
NFκβ essential modulator NEMO 
NOD-like receptor NLR 
Nuclear factor kappa-light-chain-enhancer of activated B cells NFκβ 
Nuclear magnetic resonance NMR 
Nucleotide-binding and oligomerization domain NOD 
Pathogen associated molecular pattern PAMP 
Pattern recognition receptor PRR 
PKR activator PACT 
Pyrin domain PYD 
 x 
 
Respiratory syncytial virus RSV 
Reston Ebolavirus REBOV 
Retinoic acid induced gene-I RIG-I 
RIG-I like receptor RLR 
Selenomethionine SeMet 
Sendai virus SeV 
Signal transducer and activator of transcription STAT 
Spleen tyrosine kinase SYK 
T-cell immunoglobulin mucin domain-1 TIM-1 
TAK-1 binding protein TAB 
TAR RNA-binding protein TRBP 
TIR domain-containing adaptor protein inducing IFN-β TRIF 
TIR-domain containing adapter protein TIRAP 
Toll-like receptor TLR 
Toll/Interleukin-1 receptor TIR 
TRAF family member-associated NFκβ activator binding kinase-1 TBK 
Transforming growth factor beta activated kinase -1 TAK-1 
TRIF-related adaptor molecule TRAM 
Untranslated region UTR 
Vesicular stomatitis virus VSV 
Zaire Ebolavirus ZEBOV 
 xi 
 
ABSTRACT 
Filoviruses are among the most deadly pathogens that cause acute disease in humans. 
Ebolavirus (EBOV) and marburgvirus (MARV) are the two members of this family, which 
have been documented to cause infrequent but severe outbreaks of hemorrhagic fever in 
humans. The severe pathogenesis and high lethality associated with filoviral infections, is in 
part, due to the suppression of host innate immune responses by virus-encoded proteins. 
Hence, structural and biochemical studies of filoviral proteins, to uncover the immune 
evasion mechanisms employed by filoviral proteins are an intense area of investigation. 
Previous studies on EBOV, have shown that one of the viral proteins called VP35 plays a key 
role in virus replication by functioning as a cofactor in the viral replication complex, and 
immune suppression by antagonizing the type I interferon (IFN) pathway. The C-terminal 
region of EBOV VP35 was implicated in dsRNA binding and IFN antagonism, although the 
mechanisms for immune evasion remained poorly defined. Recent work from our lab has 
resulted in crystal structures of Zaire ebolavirus (ZEBOV) and Reston ebolavirus (REBOV) 
VP35 C-terminal domain, and ZEBOV VP35 C-terminal domain bound to dsRNA. These 
studies gave new insights into the role of conserved basic residues in the C-terminal domain 
in both viral replication and immune evasion functions of VP35. These studies also 
established that mutation of residues mediating dsRNA binding also resulted in diminished 
IFN-inhibition using in vivo assays. In addition, the dsRNA bound structure suggested a 
potential mechanism by which EBOV VP35 hides viral dsRNA from detection by host RIG-I 
like receptors (RLRs). Studies addressing immune evasion mechanisms by filoviruses have 
predominantly been done on ZEBOV, and functions of MARV proteins are largely 
 xii 
 
uncharacterized and are inferred through homology to EBOV. Moreover recent reports on 
MARV proteins have shown that there are important differences in cell entry, host tropism, 
replication complex formation, and immune evasion mechanisms between the two viruses. 
The goal of my thesis work was to develop a comparative understanding of EBOV and 
MARV VP35, by characterizing MARV VP35 mediated immune evasion mechanisms using 
structural, biochemical, and cell biological studies. During the course of this study, we solved 
the crystal structure of MARV VP35 interferon inhibitory domain (IID) bound to dsRNA. 
This structure revealed several similarities with ZEBOV VP35 IID, but importantly there are 
several striking differences. Similar to ZEBOV, mutation of residues involved in dsRNA 
contacts in the MARV VP35 IID-dsRNA structure results in diminished dsRNA binding and 
IFN inhibition in vivo. While both MARV and ZEBOV VP35 IID bind to dsRNA in a 
sequence independent manner, MARV VP35 IID binds long(er) dsRNA compared to 
ZEBOV. We did not observe any interactions of MARV VP35 IID with the dsRNA blunt-
ends, as in the case ZEBOV VP35. We biochemically validated these structural differences 
by in vitro dsRNA binding assays and show that MARV VP35 IID binds preferentially to 
longer dsRNA. Moreover MARV VP35 IID is insensitive to the presence of 5’ or 3’ 
overhangs in dsRNA, whereas ZEBOV VP35 IID binds preferentially to blunt-end dsRNA 
compared to overhang containing dsRNA. In this study, for the first time, using in vitro 
ATPase assays, we show that while both MARV and ZEBOV VP35 IID can inhibit RIG-I 
activation by overhang containing dsRNA, only ZEBOV VP35 IID can inhibit RIG-I 
activation by short blunt-end dsRNA. In addition we show that both MARV and ZEBOV 
VP35 IID can inhibit MDA5 activation by poly I:C, a long dsRNA mimic, mediated ATPase 
activation. The results from this study supports a model based on both structural and 
 xiii 
 
biochemical data, in which MARV and ZEBOV VP35 IID inhibit host immune responses by 
sequestration of overlapping (double-strandedness) and distinct (blunt-ends) RNA PAMPs 
from being detected by host RIG-I like receptors. This work provides new insight into the 
structure and function of MARV VP35 IID, and advances our understanding of the structural 
basis for dsRNA binding by MARV VP35 IID and its role in IFN antagonism and immune 
evasion.  
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CHAPTER 1.  HOST INNATE IMMUNITY 
 
1.1 Introduction 
 
The immune system allows host cells to combat constant challenges by pathogen 
invasion. Even single-celled prokaryotic organisms such as bacteria have a rudimentary 
immune system in the form of proteins and restriction enzymes that can fight bacteriophage 
infections (Bikard & Marraffini, 2012). Eukaryotic organisms including plants, invertebrates 
and vertebrate animals, have evolved extremely complex immune systems to survive and 
counteract infections by pathogens. In higher eukaryotes such as vertebrates, once the 
pathogens are able to cross the physical barriers such as the epithelial and mucosal layers of 
external organs, the immune systems kicks in and is able to detect the breach in defenses 
very quickly and efficiently in order to prevent infection and clear the pathogen. The immune 
system of higher eukaryotes has two components – innate and adaptive immunity. Innate 
immunity is a quick, inherent, broad response to a variety of pathogens and serves as the first 
line of defense for the host (Akira et al, 2006). Innate immunity is mediated though the 
production of variety of chemicals such as chemokines, cytokines and other proteins that can 
counteract the pathogen (Newton & Dixit, 2012). Host immune mechanisms, whether simple 
or complex have a fundamental purpose: to recognize self from non-self. The innate immune 
system consists of specialized proteins called pattern recognition receptors (PRRs), which act 
as surveillance mechanisms to detect pathogen infections by detecting unique molecular 
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signatures called pathogen associated molecular patterns (PAMPs) (Olive, 2012). There are 
different classes of PRRs, which detect components from a variety of pathogens such as 
bacterial cell wall components, carbohydrates like lipopolysaccharide, mannose, 
peptidoglycans, bacterial peptides, fungal glycans and viral genomes such as DNA and RNA 
(Takeuchi & Akira, 2010). This triggers an inflammatory response mediated through an 
intricate network of protein-protein interactions, which results in the production of 
interferons (IFNs) and other chemokines, cytokines involved in clearing the infection.  
 
Adaptive or acquired immunity is mediated by the production of antibodies by T and 
B cells against specific antigens from pathogens presented to the immune system by 
specialized set of cells called antigen-presenting cells (APCs) such as dendritic cells (DCs) 
and macrophages (Bonilla & Oettgen, 2010). The adaptive immune response is highly 
tailored to respond to a specific pathogen. Acquired immunity also confers immunological 
memory to the host, allowing it to remember specific antigens and prevent future infections 
by mounting a strong, specific response to recurring infections. The activation of innate 
immunity is a required and necessary step for the activation of acquired immunity (Iwasaki & 
Medzhitov, 2010). Hence the two pathways are tightly coupled and regulated by host cells in 
order to modulate the overall response to infection by fine-tuning the signaling processes that 
leads to inflammation. This complexity has allowed host cells to detect and counteract a 
variety of different pathogens such as bacteria, fungi, viruses, and sometimes even 
endogenous stress signals from toxic chemicals that may be produced in the host. Pathogens 
interfere with these signaling processes, by hijacking one or more host components, resulting 
in attenuation or dysregulation of the immune response, leading to disease.   
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Pattern recognition receptors (PRRs) serve as the starting point for triggering host 
innate and adaptive immune responses through its ability to detect pathogens. Their varied 
cellular location and the ability to detect various types of molecular signatures, allow them to 
readily detect the presence of a broad range of pathogens and mobilize the innate immune 
cells. It is important to understand the mechanisms involved in PAMP recognition and signal 
transduction and how pathogens interfere with this process. This will allow us to develop 
strategies for better therapeutics, since PAMP recognition is a key early step in immune 
activation.  
 
 
1.2 Pattern recognition receptors 
 
Pattern recognition receptors (PRRs) are surveillance proteins, which detect pathogen 
associated molecular patterns (PAMPs) and initiate the innate immune responses (Takeuchi 
& Akira, 2010). The host cell is equipped to detect PAMPs at different stages of pathogen 
invasion and in different cellular compartments, since PRRs are expressed in many different 
cell types and both at the cell surface, cytosol and endosomal vesicles (Kumar et al, 2011). 
There are four major classes of PRRs, each detecting distinct molecular signatures from a 
variety of different pathogens – Toll-like receptors (TLRs), C-type lectin receptors (CLRs), 
NOD-like receptors (NLRs), and RIG-I like receptors (RLRs). The TLRs and CLRs help 
detect pathogens at the cell surface or in the endosome, whereas the NLRs and RLRs are 
cytoplasmic receptors (Takeuchi & Akira, 2010). All of these different PRRs trigger innate 
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and adaptive immune responses through an intricate network of distinct and overlapping 
pathways. There is also a significant level of crosstalk among these pathways, which serves 
to fine tune the immune response depending on the severity and the variety of pathogens that 
the host cell encounters (Crozat et al, 2009).  
 
1.3 Toll-like receptor signaling 
The TLRs are integral membrane proteins, which can be located either in the plasma 
membrane or the endosomal compartment. The TLRs recognize a variety of PAMPs such as 
single-stranded and double-stranded RNA and DNA. TLRs recognize their ligands through 
an ectodomain and transduce the signal through their cytoplasmic domains to downstream 
adapter proteins to initiate the production of chemokines and cytokines that help combat the 
infection (Figure 1-1). TLRs consist of a cytoplasmic Toll/Interleukin-1 receptor (TIR) 
domain and an extracellular receptor domain composed of 19-25 leucine-rich repeats (LRRs) 
(Gay & Gangloff, 2007) (Figure 1-2A). Of the different members of this family of proteins, 
TLR1, 2, 4, 5, 6 are expressed at the plasma membrane where they detect a broad range of 
PAMPs from bacteria, fungi and protozoans such as lipopolysaccharide (LPS), flagellin, 
peptidoglycans, unmethylated CpG, lipophosphoglycan (LPG) (Gay & Gangloff, 2007; 
Langefeld et al, 2009; Sorbara & Philpott, 2011). TLRs 3, 7, 8 and 9 are found in endosomal 
membranes and play critical roles in the context of recognizing viral infections by 
recognizing viral nucleic acids. Of these TLR3 is specific for viral double-stranded RNA 
(dsRNA) 
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Figure 1-1. TLR mediated signaling.  
TLRs are activated by a wide range of bacterial, fungal and viral PAMPs. Ligand induced 
dimerization of TLRs trigger signaling through MyD88-dependent and independent 
pathways to activate NF-κβ and IRF-3/7 transcription factors which turn transcription of 
genes under the control of NF-κβ and IFN-β promoters respectively. In addition TLRs can 
also activate the AP-1 transcription factor through the MAP kinase pathway. 
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and poly I: C, TLR7, 8 recognize viral single-stranded RNA (ssRNA), while TLR9 
recognizes viral genomic DNA (Akira & Takeda, 2004; Barton & Medzhitov, 2003).  
TLR3 is of specific importance in the detection of viral infections, since it recognizes 
dsRNA, a viral PAMP. Its localization at the endosomal membrane allows it to detect RNA 
genome containing virus, which is internalized into the cell through endocytosis. The 
ectodomain or receptor domain of TLRs including TLR3, contain a series of leucine-rich 
repeats with the consensus sequence XLXXLXLXXNXLXXLXXXXFXXLX, where X 
represents any amino acid (Bell et al, 2005). The length and post-translational modifications, 
most commonly N-linked glycosylation, of the LRRs differ among the different classes of 
TLRs. These LRR motifs enforce a distinct solenoid structure bent into a horseshoe shape 
with each LRR sequence making up one turn of the solenoid (Figure 1-2B) (Bell et al, 2006; 
Bell et al, 2005). The hydrophobic leucine residues all point inwards into the concave surface 
of this horseshoe structure forming a hydrophobic core. In most TLRs, ligand binding occurs 
through this concave surface of the ectodomain (Bell et al, 2005). Similar to other TLRs, the 
TLR3 ectodomain is highly glycosylated with atleast 15 proposed N-linked glycosylation 
sites (Botos et al, 2011; Sun et al, 2006). The residues that get glycosylated are distributed 
throughout the structure. The ectodomain also has specific motifs, which cap the N and the 
C-terminus called LRR-NT and LRR-CT respectively, the structures of which differ among 
the different TLRs (Bell et al, 2006; Botos et al, 2011). The crystal structure of TLR3 bound 
to 46bp dsRNA gave new insight into the nature of ligands that TLR3 binds and the 
conformation of the TLR3 dimer, which serves as the active signaling entity. Two molecules 
of TLR3 ectodomains bind to the 46bp dsRNA, to form an M-shaped structure, where the 
dsRNA binds near the N and the C-terminus of both molecules (Figure 1-2C). The two TLR3 
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molecules interact with each other through their respective LRR-CT regions (Gay & 
Gangloff, 2007; Liu et al, 2008; Kang & Lee, 2011). This explains why a minimum length of 
45bp dsRNA is required to activate TLR3, because all of the above interactions are required 
to form the active signaling complex. The dsRNA interactions are only the phosphodiester 
backbone and hence it is a sequence independent mode of recognition. Of specific note are 
four histidine residues in TLR3, which bind to the phosphate groups of dsRNA, and regulate 
the pH dependent binding of TLR3 to dsRNA. TLR3 only interacts with dsRNA at the 
endosomal pH of near 6.5, since the imidazole rings of the histidine would be deprotonated at 
physiological pH (Liu et al, 2008). Upon ligand binding, the TLR ectodomain dimerization 
(Figure 1-2C) drives the cytoplasmic TIR domains of two TLR molecules to come into close 
contact with each other. The TIR domains are protein-protein interaction motifs containing 
the signature death domain (DD) fold (Figure 1-1D) (Barton & Medzhitov, 2003; Botos et al, 
2009; Leonard et al, 2008).  
This dimerization allows it to recruit adapter proteins such as myeloid differentiation 
primary-response protein 88 (MyD88) and TIR-domain containing adapter protein (TIRAP) 
(Figure 1-2) (Liu et al, 2008; Takada et al, 2007). MyD88 also contains a TIR domain and 
helps recruit other death domain fold containing members of the signaling complex through 
protein-protein interactions (Botos et al, 2009; de Bouteiller et al, 2005; Leonard et al, 2008). 
For example MyD88 is known to recruit the interleukin-1 receptor associated kinases 
(IRAKs) through protein-protein interactions mediated by  
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Figure 1-2. Structural basis for dsRNA recognition by TLR3.  
(A) The domain organization of representative TLR member TLR-3. The extracellular 
receptor domain at the N-terminus region has a tandem LRR rich domain connected to the 
cytoplasmic signaling TIR domain through a transmembrane region. (B) Crystal structure of 
the receptor domain of TLR-3 (purple) shows the signature horseshoe shaped solenoid 
structure (PDB 3CIG) (Liu et al, 2008). (C) Crystal structure of TLR3 bound to dsRNA 
(blue) shows the ligand induced dimerization of the receptor domain (PDB 3CIY) (Liu et al, 
2008). (D) The C-terminal TIR domain of TLR10 shows the canonical death domain fold 
containing two alpha helical subdomains (light and dark brown) (PDB IT3G) (Khan et al, 
2004). 
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their death domains. Upon assembling the different IRAKs, they undergo 
autophosphorylation and trans-phosphorylation, which results in binding of and tumor 
necrosis factor receptor-associated factor 6 (TRAF6) to the IRAKs (Figure 1-2). The IRAKs-
TRAF6 complex associates with another protein complex consisting of the transforming 
growth factor beta activated kinase (TAK1) and TAK1-binding proteins (TABs). The 
activated TAK1 complex phosphorylates both mitogen activated protein kinases (MAPK) 
and the IKK complex (Barton & Medzhitov, 2003; Jenkins & Mansell; Verstak et al, 2009). 
The phosphorylation of MAPK leads to activation of transcription factors such as activator 
protein-1 (AP-1).  The TAK1 complex also phosphorylates and activates the IKK complex 
which is composed of three subunits – IKK-α, IKK-β and IKK-γ which is also called as NF-
κβ essential (NEMO) (Figure 1-2). The function of this IKK complex is to regulate the 
transcription factor NF-κβ, which is a protein complex composed of homo or heterodimers of 
one of several proteins – REL-A, REL-B, REL, p50, p52 and p65 (Brasier, 2006; Gilmore, 
1999). These dimers are held in an inactive conformation in the cytoplasm by the inhibitor of 
NF-κβ kinase (IκB). TAK1 activation of the IKK complex, leads to phosphorylation of IκB, 
which leads to its poly-ubiquitination and proteasomal degradation thus activating the NF-κβ 
dimer (Karin & Ben-Neriah, 2000). The activation of the transcription factors such as AP-1 
and NF-κβ result not only in the production of the type I IFNs such as IFN-β, which is a key 
component of the innate immune response, but also serves as a necessary step for the 
activation of the adaptive immune response by producing chemokines (such as IL-6, IL-1β 
and IL-12), chemokine receptors, cell-adhesion molecules and other co-stimulatory 
molecules (Iwasaki & Medzhitov, 2004). In addition to the MyD88/TIRAP dependent 
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signaling and activation of NF-κβ, some members of the TLRs such as TLR3 and 4, activate 
the transcription factors called interferon regulatory factors (IRF) 3 and 7, which stimulate 
IFN-β production. This is mediated by another pathway, which is dependent on recruitment 
of another set of adaptor proteins called TIR domain-containing adaptor protein inducing 
IFN-β (TRIF) and TRIF-related adaptor molecule (TRAM) (Akira & Takeda, 2004; Kawai & 
Akira, 2010). These two adapter proteins result in the autophosphorylation and activation of 
the IFN kinases IKK-ε and TRAF family member associated NF-κβ activator (TANK)-
binding kinase-1 (TBK-1) (Kawai & Akira, 2007). These kinases then phosphorylate and 
activate IRF-3 and IRF-7, which dimerize and localize to the nucleus where they turn on the 
transcription of type I interferons (Figure 1-1). Thus TLR mediated signaling can activate the 
production of cytokines, chemokines (such as IL-6, IL-1β and IL-12), chemokine receptors 
through multiple pathways and serves not only to trigger the innate immune response but also 
acts as a necessary precursor for the activation of the adaptive immune response.  
 
1.4 C-type lectin receptor signaling 
The CLRs are a class of membrane bound PRRs which recognize carbohydrate motifs 
in various pathogens. These proteins contain a conserved carbohydrate recognition domain 
(CRD) through which it detects various ligands in a calcium-dependent manner (Geijtenbeek 
& Gringhuis, 2009; Hollmig et al, 2009). CLRs are expressed in a variety of cells including 
macrophages, natural killer (NK) cells and dendritic cells (DCs) (McGreal et al, 2005), which 
are antigen-presenting cells and play a critical role in modulating the adaptive immune 
response by activating multiple signaling cascades in a carbohydrate-specific manner 
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(Geijtenbeek & Gringhuis, 2009). CLRs recognize a wide variety of PAMPs such as 
mannose, fucose, N-acetyl glucosamine, and β-glucans (Weis et al, 1998). In addition CLRs 
also regulate migration, adhesion and antigen uptake and presentation in DCs (Figdor et al, 
2002). Structural studies on DC-SIGN and mannose receptors have given insights into the 
specificity and mechanism of ligand recognition by the carbohydrate recognition domains of 
these proteins (Feinberg et al, 2000; Feinberg et al, 2009). The CRDs of both DC-SIGN and 
mannose receptors adopt the typical C-type lectin fold (Figure 1-3A). In the case of DC-
SIGN, both the terminal N-acetyl glucosamine and an internal mannose residue of the 
oligosaccharide interacts both directly and through the calcium ion via hydrogen bonds and 
hydrophobic interactions (Figure 1-3A). The CRD of mannose receptor has a similar fold to 
DC-SIGN but binds only to the terminal N-acetyl glucosamine moiety of the oligosaccharide,  
while the rest of the ligand points away from the protein (Figure 1-3B).  
 
CLRs can be divided into two major types – group I and group II. The group I CLRs 
contain multiple carbohydrate recognition domains (CRDs) (Figure 1-3B) in the N-terminus, 
whereas the group II members contain a single CRD in the C-terminus (Weis et al, 1998). 
The macrophage mannose receptor (MMR), DEC-205 and related family of proteins belong 
to the group I CLRs. The asialoglycoprotein receptor family of proteins which include DC-
associated C-type lectin-1, 2 (DECTIN-1, 2), macrophage-inducible C-type lectin 
(MINCLE), dendritic cell-specific ICAM3-grabbing nonintegrin (DC-SIGN), DC 
immunoreceptor (DCIR), myeloid C-type lectin-like receptor (MICL) and  
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Figure 1-3. Structural basis for carbohydrate recognition by CLRs.  
(A) The carbohydrate recognition domain (CRD) of DC-SIGN receptor (cartoon 
representation) bound to a pentasaccharide (stick representation) (PDB 1K9J) (Feinberg et al, 
2001). Magenta spheres represent the three calcium ions bound to the protein. (B) CRD of rat 
mannose receptor (cartoon representation) (2IT5) bound to high mannose oligosaccharide 
(stick representation) (Feinberg et al, 2000). Magenta spheres represent the three calcium 
ions bound to the protein. 
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DC NK lectin group receptor-1 (DNGR-1) belong to group II (Brown et al, 2007; Hollmig et 
al, 2009). Recent studies have shown that there are two major pathways that the CLR 
mediated signaling triggers host immune responses. CLRs such as DC-SIGN, DCIR and 
MICL mediate signaling by phosphorylation and activation of the Ser/Thr kinase called 
RAF1 (Figure 1-4) (Gringhuis et al, 2009; Gringhuis et al, 2007). RAF1 subsequently 
phosphorylates the p65 subunit of the NF-κβ complex, which results in activation and 
nuclear retention of the complex. The alternate pathway involving the DECTIN-1, 2 and 
MINCLE receptors involves interactions with immunoreceptor tyrosin-based activation motif 
(ITAM) containing adaptor molecules such as Fc receptor γ-chain (FcRγ) (Kerrigan & 
Brown). This activates the spleen tyrosine kinase (SYK), which mediates NF-κβ and AP-1 
activation by targeting multiple downstream effector proteins (Figure 1-4) (Gringhuis et al, 
2009; Gringhuis et al, 2007; Kerrigan & Brown; Kingeter & Lin). In addition there is cross-
talk between the SYK and the RAF1 pathways to negatively regulate TLR mediated 
signaling to modulate NF-κβ activation in response to extracellular cues (Geijtenbeek & 
Gringhuis, 2009; Hollmig et al, 2009). Taken together, all of these data suggest that CLRs 
play a very important role in the functioning of the immune system, especially due to their 
expression on the surface of antigen presenting cells such as dendritic cells. Although the 
exact signaling mechanisms triggered by CLR ligand recognition is unclear, it is becoming 
increasingly apparent that it likely involves networking with the other innate immune 
receptors, especially TLRs. 
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Figure 1-4. CLR mediated signaling.  
CLRs are activated by a broad range of bacterial and fungal carbohydrate PAMPs. Ligand 
induced dimerization of TLRs trigger signaling through two independent pathways, one 
mediated through RAF-1 kinase and the other through the SYK kinase. These pathways lead 
to the activation of activate NF-κβ and AP-1 transcription factors resulting in inflammatory 
response.  
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1.5 NOD-like receptor signaling  
 
The nucleotide-binding oligomerization domain (NOD)-like receptors are 
cytoplasmic proteins, which detect a broad range of microbial PAMPs including 
peptidoglycans from bacterial cell wall and viral PAMPs such as RNA (Franchi et al, 2006). 
The common feature among the different NLRs is the tripartite domain organization. They 
are classified into different types based on the different N-terminal effector domains such as 
caspase activation and recruitment domain (CARD), Pyrin domain (PYD) or baculovirus 
inhibitor repeat (BIR) domain (Franchi et al, 2006; Sirard et al, 2007). All NLRs share a 
central nucleotide-binding and oligomerization domain and a C-terminal receptor domain 
characterized by leucine-rich repeats (LRRs). The NLRs are in an autoinhibited conformation 
in which the receptor domain interacts with the NOD domain and upon recognition of 
PAMPs by the LRR, the NLRs undergo conformational changes resulting in oligomerization 
and downstream signaling mediated by the NOD domain (Langefeld et al, 2009; Proell et al, 
2008). Recent structural work on NLRX1, a family member of NLRs present in the 
mitochondria has resulted in the crystal structure of the C-terminal ligand-binding domain 
(Hong et al, 2012) (Figure 1-5). The C-terminal domain of NLRX1 shows the typical 
arrangement of the tandem LRRs arranged in a curved, crescent shape with the concave 
hydrophobic core pointing inwards (Figure 1-5A). There are 8 LRR sequences in NLRX1 
and they are capped at the N- and the C-terminus by alpha-helical LRR-NT and LRR-CT 
motifs (Hong et al, 2012; Moore et al, 2008; Ye & Ting, 2008). The crystal structure shows 
that this domain of the protein forms a dimer through extensive interactions between the 
LRR-CT motifs (Figure 1-5A). Positively charged patches identified via the structure and  
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Figure 1-5. Structure of the ligand binding domain of NOD-like receptor.  
(A) Cartoon representation of the C-terminal ligand binding domain of NLRX1 shows the 
three typical regions – the LRR-NT cap region (red), the LRR region (blue) containing eight 
tandem LRR motifs, and the LRR-CT region (yellow) (PDB 3UN9) (Hong et al, 2012). The 
dimerization of the ligand-binding domain is mediated through the LRR-CT region. (B) The 
hexameric ring-like arrangement of the ligand-binding domain of NLRX1 as a result of the 
trimerization mediated by the LRR-NT region (red) (PDB 3UN9) (Hong et al, 2012). 
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mutational analysis has been shown to be important for NLRX1 binding to single-stranded 
and double-stranded RNA (Hong et al, 2012). Also the NLRX1 C-terminal domain dimer 
trimerizes through the LRR-NT, resulting in a hexameric ring-like arrangement, that lends 
support to the hypothesis that upon ligand binding, NLRX1 may assemble into a ring-like 
structure and helps to recruit downstream effector proteins (Figure 1-5B).  
Upon ligand binding, the CARD domains of NLRs interacts with downstream CARD 
containing Ser/Thr kinase receptor-interacting kinase 2 (RIP2) (Figure 1-6) (Kufer, 2008; 
Langefeld et al, 2009; Shaw et al). Activation of RIP2, results in phosphorylation and 
activation of the IKK complex, which in turn activates NF-κβ by phosphorylating and 
targeting Iκβ for degradation (Brasier, 2006; Gilmore, 1999; Kufer, 2008). In addition RIP2 
also activates the MAPK pathway resulting in the activation of AP-1. The PYD containing 
NLRs are called NALPs and they detect a variety of bacterial components including flagellin 
(Proell et al, 2008).  
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Figure 1-6. NLR mediated signaling.  
NLRs are cytoplasmic PRRs activated by bacterial PAMPs such as DAP and MDP. Ligand 
binding leads to activation of NLRs which signal through the adaptor protein RIP-2 to 
activate both the IKK complex and MAPK pathways to trigger nuclear translocation of AP-1 
and NF-κβ transcription factors.  
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Upon detection, they undergo conformational change and oligomerization and recruit the 
downstream adapter protein called ASC, which has a PYD and CARD. The NALPs interact 
with ASC through a PYD-PYD interaction, while a CARD-CARD interaction helps recruit 
and activate Caspase 1. Assembly of this multi-protein complex called the inflammasome 
leads to the recruitment of several Caspase 1 molecules and leads to proteolytic processing 
and maturation of IL-1β and IL-18 (Shaw et al; Williams et al). These cytokines are then 
secreted to induce the type II interferons and NK cell activation. The BIR domain containing 
NLRs are called neuronal apoptosis inhibitory proteins (NAIPs) and also assemble 
inflammasomes leading to Caspase 1 recruitment and activation upon ligand binding. Thus 
NLR activation leads to signaling cascades, which link the innate and the adaptive immune 
responses (Shaw et al; Williams et al).  
 
1.6 RIG-I-like receptor signaling 
The retinoic acid-inducible gene I (RIG-I)-like receptor family of proteins are 
cytoplasmic PRRs, which play a key role in host antiviral responses by detecting viral 
PAMPs, especially viral dsRNA (Fairman-Williams et al, 2010). The RLRs have three 
members RIG-I, melanoma differentiation associated gene 5 (MDA5) and laboratory of 
genetics and physiology 2 (LGP2). RIG-I and MDA5 contain two tandem N-terminal caspase 
activation and recruitment domains (CARDs), which are protein-protein interaction motifs 
and are essential for signaling (Leung et al, 2012; Loo & Gale, 2011). It has been shown that 
over-expression of the CARD domains of RIG-I serves as a constitutive activator of type I 
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IFN, suggesting that the CARD domains are required and sufficient for downstream 
signaling (Binder et al, 2011; Loo & Gale, 2011). LGP2 lacks the CARD domains and cannot 
take part in signaling; hence may play a role in negative regulation of RIG-I and MDA5 
(Rothenfusser et al, 2005; Yoneyama et al, 2005). All three proteins consist of a central 
tripartite DEX/DH domain called helicase domains 1 and 2 (Hel1 and 2) and a helicase 
insertion domain (Heli) in addition to a C-terminal RNA binding domain (RBD). RIG-I and 
MDA5 are known to be activated by distinct and overlapping RNA ligands (Kato et al, 2006; 
Loo et al, 2008; Yoneyama et al, 2005). RIG-I has been shown to be activated by RNA 
containing a 5-triphosphate cap and short double-stranded regions whereas MDA5 has been 
linked to the recognition of longer dsRNA and its synthetic analogue poly I:C (Leung & 
Amarasinghe, 2012; Leung et al, 2012; Lu et al, 2010; Yoneyama et al, 2004). 
Correspondingly some viruses trigger RIG-I or MDA5 selectively and some viruses trigger 
both.  For example, members of the single-stranded negative sense RNA genome viruses 
such as rabies virus, vesicular stomatitis virus (VSV), Sendai virus (SeV), influenza virus, 
Newcastle disease virus (NDV), respiratory syncytial virus (RSV) have been shown to 
selectively trigger RIG-I mediated immune responses. On the other hand, long dsRNA 
genome containing viruses such as picornaviruses trigger MDA5 mediated responses (Loo et 
al, 2008; Yoneyama et al, 2005). Recent structural and functional studies on RIG-I have 
resulted in a model for the mechanism of activation by dsRNA (Jiang et al, 2011; Kageyama 
et al, 2011; Kowalinski et al, 2011; Lu et al, 2010; Luo et al, 2011). Crystal structures of full 
length RIG-I in the absence of dsRNA suggests that the helicase insert domain is engaged in 
intramolecular protein-protein interactions with the CARD domains keeping RIG-I in a 
closed, autoinhibited conformation by masking the CARD domains (Figure 1-7A). RIG-I 
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dsRNA complex structures show that upon dsRNA binding, RIG-I undergoes a conformation 
change, in which the helicase and the C-terminal domains are engaged in protein-RNA  
 
 
Figure 1-7. Structure of autoinhibited and dsRNA-bound RIG-I.  
(A) Cartoon representation of the autoinhibited conformation of full-length duck RIG-I 
showing the first N-terminal CARD domain (magenta), second CARD domain (blue), 
helicase insert domain (yellow), helicase-2 domain (cyan), regulatory pincer domain (red) 
and helicase-1 domain (green) (PDB 4A2W) (Kowalinski et al, 2011). (B) Cartoon 
representation of RIG-I-dsRNA complex structure showing the helicase domains (same 
coloring scheme as figure A) and the C-terminal RNA binding domain (orange) bound to 
dsRNA (magenta) (PDB 2YKG) (Luo et al, 2011) 
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contacts and the N-terminal CARD domains are free to interact with downstream CARD 
containing proteins like IPS-1 (Figure 1-7B) (Cui et al, 2008; Kowalinski et al, 2011; Leung 
& Amarasinghe, 2012; Luo et al, 2011; Weis et al, 1998; Yoneyama & Fujita, 2009). Thus 
the C-terminal and the helicase domains act as regulatory elements of RIG-I and MDA5 by 
keeping the CARD domains masked until ligand recognition occurs. In addition crystal 
structures of the RD of RIG-I in complex with dsRNA has shown that this domain is 
responsible for the recognition of the 5’-triphosphate cap of dsRNA through a network of 
hydrogen bonds and base-stacking interactions mediated by conserved hydrophobic and basic 
residues, although it can also bind to blunt end dsRNA (Gringhuis et al, 2009; Li et al, 2009; 
Lu et al, 2011; Lu et al, 2010). A number of recent studies have also studied the implications 
of MDA5 interactions with long dsRNA and poly I:C. These studies suggest that the CARD 
domains in RIG-I and MDA5 may be arranged differently in the context of the full-length 
protein, suggesting that their activation mechanisms will likely be different as well (Berke & 
Modis, 2012; Peisley et al, 2011). Electron microscopic (EM) analysis of MDA5 suggest that 
it tends to form long filamentous structures upon addition of long dsRNA, and the formation 
of such structures is mediated by cooperative binding of dsRNA (Berke & Modis, 2012; 
Peisley et al, 2011). However, the exact nature of the physiological RNA ligands and the 
structural basis for the differences in ligand recognition and its role in activation of RIG-I 
and MDA5 is still unclear. 
 
Although the activation mechanisms of RIG-I and MDA5 may be different they share 
a common downstream signal transduction pathway. Upon activation, the CARD domains of 
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RIG-I and MDA5 interact with the CARD domain of the downstream adapter protein IPS-1 
(Figure 1-8). IPS-1 contains a proline-rich region and a transmembrane domain, which keeps 
it anchored to the outer mitochondrial membrane (Broquet et al, 2011; Seth et al, 2005). 
Although it has been shown that IPS-1 anchoring to the mitochondrial membrane is 
absolutely essential for type I IFN signaling, the functional importance for this is still not 
understood. The proline-rich region is involved in recruiting a number of signaling molecules 
such as TRIF, TRAM, MyD88 and RIP1. Hence the signals transmitted through the TLRs 
and RLRs converge at this point and through conserved signaling mechanisms activate the 
transcription factors such as NF-κβ, IRF-3 and IRF-7 resulting in the production of 
inflammatory chemokines and cytokines (Crozat et al, 2009; Gack et al, 2007; Hausmann et 
al, 2008; Leung & Amarasinghe, 2012; Loo & Gale, 2011; Ramos & Gale, 2011) (Figure 1-
8). 
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Figure 1-8. RLR mediated signaling.  
RLRs are activated by short and long viral dsRNA ligands. Ligand induced conformational 
change of RLRs trigger signaling via the mitochondrial adapter protein IPS-1. IPS-1 activates 
the IFN kinases, which lead to activation of the IRF-3/7 transcription factors and production 
of type I IFN. 
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1.7 Type I IFN signaling pathway 
Interferons are ubiquitously expressed cytokines that play a critical role in mediating 
innate immune responses, especially against viral infections. There are two major types of 
interferons, type I (includes IFN-α and β among others) and type II (IFN-γ). All type I IFNs 
bind to the cell surface receptor called type I IFN receptor, which consists of two subunits 
called IFNAR1 and 2. IFN-γ binds to the type II IFN receptor, which is also made of two 
subunits called IFNGR1 and 2 (de Weerd & Nguyen, 2012; Uze et al, 2007). These receptors 
are associated to intracellular non-receptor tyrosine kinases, which belong to the Janus kinase 
(JAK) family (Figure 1-9). IFNAR1 interacts with TYK2 and IFNAR2 interacts with JAK1 
(Bonjardim et al, 2009; Onomoto et al, 2010). Upon ligand binding induced dimerization of 
the IFNAR receptor, the JAK1 and TYK2 kinases are activated through autophosphorylation. 
This triggers the canonical JAK-STAT pathway, in which the JAK1 and TYK2 
phosphorylate and activate transcription factors called signal transducer and activation of 
transcription (STATs) (Monie et al, 2009; Zuniga et al, 2007).   The STATs activated by type 
I IFNs include STAT1, 2, 3 and 5. Upon phosphorylation and activation, the STAT proteins 
form homodimers and different heterodimers and translocate to the nucleus. These STAT 
complexes then associate with another transcription factor called interferon regulatory factor 
9 (IRF9), to form the mature ISGF3 complex, which binds to the specific promoter sequences 
called IFN-stimulated response elements (ISRE) and triggers the production of IFN stimulate 
genes (ISGs) (Figure 1-9) (Bonjardim et al, 2009).  
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The IFNGR1 and 2 are associated with JAK1 and JAK2 kinases respectively, and 
upon IFN-γ binding, these kinases trigger the phosphorylation and activation of 
predominantly STAT1 proteins, which form homodimers. The STAT1-STAT1 homodimer, 
then relocates to the nucleus where it binds to another specific promoter sequence called 
IFN-γ activated site (GAS) (van Boxel-Dezaire & Stark, 2007). While type I IFNs can also 
stimulate the induction of both ISRE and GAS regulated genes, IFN-γ is specific to the GAS 
element. Together the type I and II IFNs induce the production of a number of antiviral 
genes, that are important for mediating not only the innate immune response, but also 
upregulate many proteins that are necessary components of the adaptive immune response. 
Similar to the signaling pathways mediated by the various PRRs, there is considerable 
crosstalk between the type I and II IFN signaling pathways, the implications of which are not 
completely understood (Bonjardim et al, 2009; Crozat et al, 2009; Zuniga et al, 2007). 
 
1.8 Viral inhibitors of innate immune responses 
 
Viruses encode proteins that antagonize and attenuate the host innate immune 
responses by a variety of different mechanisms. RNA viruses in particular encode for 
proteins that target TLR3, RIG-I and MDA5 and their downstream signaling components, 
since these are the host receptors that recognizes viral RNA PAMPs. These viral proteins can 
be broadly classified into two types – inhibitors of type I IFN production and inhibitors of 
type I IFN responses. Inhibition of type I IFN production is a common mechanism adopted  
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Figure 1-9. IFN mediated signaling.  
Type I and II IFNs are recognized by cell surface receptors called IFNAR1/2 and IFNGR1/2 
respectively, which activate the JAK-STAT pathways mediated by the Jak1/2 and Tyk2 
kinases. This results in phosphorylation of the STAT transcription factors which turn on the 
transcription of ISGs. 
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by many different families of viruses. In the case of picornaviruses, type I IFN production is 
inhibited by the targeted proteolysis of MDA5 (Barral et al, 2007). The cleavage of MDA5 is 
not carried out by virus-encoded proteases such as 2Apro or 3Cpro, instead viral infection 
targets MDA5 to be degraded by caspases and the proteasomal pathway (Barral et al, 2007). 
RIG-I is also degraded in cells infected with poliovirus, rhinoviruses, echovirus, and 
encephalomyocarditis virus. In contrast to MDA-5, cleavage of RIG-I is not accomplished by 
cellular caspases or the proteasome. Rather, the viral proteinase 3C(pro) cleaves RIG-I, both 
in vitro and in cells (Barral et al, 2009). It has also been shown that in the case of 
paramyxoviruses such as measles, mumps, simian virus 5, Newcastle disease virus, Sendai 
virus, and human parainfluenza viruses, the highly conserved cysteine-rich C-terminal 
domain of the V proteins is involved in directly binding to MDA5 (Andrejeva et al, 2004). 
Using reporter gene assays, it has been shown that MDA5 overexpression stimulates both 
IRF-3 and NF-κβ transcription factors and that paramyxovirus V protein can block the 
MDA5 mediated activation of both these transcription factors (Andrejeva et al, 2004). In the 
case of human respiratory syncytial virus (RSV), NS2 directly binds to the N-terminal CARD 
domains of RIG-I, thus preventing the downstream effectors such as IPS-1 from interacting 
with the RIG-I CARDs (Ling et al, 2009). As a result, NS1 or NS2 deleted RSVs induce 
more IFN production than wild-type RSV in infected cells (Bossert et al, 2003; Jin et al, 
2000). NS2 expression inhibits IFN transcription induced by both the RIG-I and TLR3 
pathways (Ling et al, 2009). NS2 is thus able to antagonize both type I IFN production by 
direct inhibition of RIG-I and and type I IFN signaling by targeting STAT1 for degradation. 
The arenavirus Z protein directly interacts with RIG-I and prevents its association with the 
mitochondria-associated IPS-1 adapter protein (Fan et al, 2010). The expression of 
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arenavirus Z proteins also attenuates the activation of transcription factors NF-κβ and IRF-3 
in infected cells (Fan et al, 2010). TRIM25 is a host protein with ubiquitin ligase activity, 
which mediates Lysine 63 linked ubiquitination of the N-terminal CARD domains of the 
RIG-I like receptor proteins (Gack et al, 2007). This ubiquitination activity is necessary for 
RIG-I mediated signal transduction and downstream IFN production. The NS1 protein from 
influenza virus inhibits the TRIM25 mediated ubiquitination of RIG-I, thus antagonizing IFN 
production (Gack et al, 2009). The aspartate residues 96 and 97 in NS1 interact with the 
coiled-coiled motif in the TRIM25 protein and prevent its oligomerization (Donelan et al, 
2003). This is an example of an indirect mechanism by which viruses are able to inhibit RIG-
I mediated signaling and IFN production. Another example is the Hepatitis C virus, which 
evades the innate immune responses by encoding for a protease NS3/4A, which cleaves the 
mitochondrial associated adapter proteins IPS-1. This cleavage of IPS-1 happens at residue 
508, which is a cysteine, resulting in the removal of the N-terminal fragment of IPS-1 from 
the outer mitochondrial membrane (Li et al, 2005). NS3/4A binds to and co-localizes with 
MAVS in the mitochondrial membrane, and has been shown to cleave IPS-1 using in vitro 
experiments. This results in loss signaling through both the TLR3 and RIG-I like receptors 
both of which signal through the adapter protein IPS-1. Recent studies have suggested that 
filoviruses such as the Zaire ebolavirus (ZEBOV) can inhibit IFN production through its 
VP35 protein using multiple mechanisms which inhibit RIG-I recognition of viral RNA 
PAMPs and IRF-3/7 phosphorylation by the IFN kinases IKK-ε and TBK-1 (Basler et al, 
2003; Basler et al, 2000; Hartman et al, 2004; Leung et al, 2009; Leung et al, 2010; Prins et 
al, 2009). Since the activation of NF-κβ is an important step in the innate immune response 
many viruses encode for proteins, which consist of ankyrin repeats in order to inhibit NF-κβ, 
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by targeting the regulatory protein NEMO (Wyler et al, 2007). Microplitis demolitor 
bracovirus encodes for protein, which is a molecular mimic of Iκβ and perform a similar 
functional role by binding to NF-κβ, preventing its phosphorylation and activation and 
retains it in the cytoplasm (Bitra et al, 2012). A238L protein from African swine fever virus 
also directly interacts with NF-κβ and prevents its nuclear transport (Silk et al, 2007). The 
Vaccinia virus N1 protein inhibits NF-κβ by inhibiting the IκB degradation, thus keeping 
NF-κβ in an inactive state (Maluquer de Motes et al, 2011). 
 
The second class of viral proteins targets the components of the JAK-STAT pathway, 
which is activated upon binding of the secreted type I and type II IFNs to their respective 
cell-surface receptors, and phosphorylation of the receptor associated Janus family kinases. 
The STAT transcription factors are common factors, which result in establishment of 
antiviral state induced by both type I and II interferons. Many viruses encode proteins that 
inhibit IFN mediated signaling by interfering with STAT proteins. For example, both NS1 
and NS2 proteins from respiratory syncytial virus have been shown to block IFN signaling by 
causing the proteasomal degradation of STAT2 (Lo et al, 2005). The simian virus V protein 
inhibits interferon signaling by targeting STAT1 for proteasomal degradation (Didcock et al, 
1999). The Nipah virus V protein directly binds to STAT1 and STAT2 proteins to form high 
molecular-weight complexes that retain STAT proteins in the cytoplasm and prevents its 
translocation to the nucleus (Rodriguez et al, 2002). Vaccinia virus encodes for the CH1 
protein, which has phosphatase activity, and this proteins binds to STAT proteins, 
dephosphorylates it and reverses its activation by the Janus kinases, thus inhibiting IFN 
mediated signaling in infected cells (Najarro et al, 2001). Recent studies have demonstrated 
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that filoviral proteins ZEBOV VP24 and MARV VP40 inhibit JAK-STAT signaling through 
distinct mechanisms. ZEBOV VP24 prevents the nuclear transport of phosphorylated STAT 
proteins by interacting with the karyopherin-α family of proteins, which are involved in 
shuttling cargo proteins across the nuclear-pore complex (Mateo et al, 2010; Reid et al, 2006; 
Reid et al, 2007). MARV VP40 on the other hand inhibits STAT phosphorylation by 
interacting with the upstream Janus kinases such as JAK1 (Valmas & Basler, 2011; Valmas 
et al, 2010).  
 
1.9 Conclusions 
 
Given the importance of interferons in triggering host innate and adaptive immunity, 
viruses encode proteins that interfere with both with IFN production and IFN mediated 
signaling through multiple mechanisms, both during early and late stages of infection. Some 
of these mechanisms involve hiding viral PAMPs from being recognized by host PRRs, 
interfering with components of the PRR mediated signaling cascade that mediate IFN 
production, and antagonizing IFN-mediated signaling by interfering with the JAK-STAT 
pathway. Filoviruses, which are the focus of my thesis also encode for proteins such as VP35 
and VP24 from ZEBOV and VP40 from MARV, which antagonize the type I IFN pathway. 
Given that there are currently no approved treatments for filoviral infections, understanding 
the molecular details of the interactions between host and viral proteins that modulate the 
IFN responses, is key for identification of target proteins against which antivirals and 
therapeutics can be targeted.  
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CHAPTER 2. FILOVIRUSES OVERVIEW 
2.1 Introduction 
 
The Filoviridae family of viruses, which includes ebolavirus (EBOV) and 
marburgvirus (MARV), are some of the most deadly pathogens known to infect humans. 
Outbreaks of these viruses have been infrequent but highly lethal. So far five species of 
EBOV – Ebola, Reston, Sudan, Tai Forest, and Bundibugyo have been identified(Feldmann 
& Geisbert, 2011). The MARV genus has only one species - Lake Victoria. Named after the 
German city Marburg, MARV was the first filovirus to be identified in 1967, during a deadly 
outbreak, when animal handlers working in Germany and Yugoslavia came into contact with 
bodily fluids of Green monkeys imported from Africa(Bausch et al, 2006; Gear et al, 1975). 
Ebolavirus was isolated in Central Africa in 1976 when an outbreak occurred in the 
Democratic Republic of Congo(1978b). Both Zaire and Sudan ebolavirus have caused deadly 
outbreaks in Africa, while there has been only one non-fatal, reported case of the Tai Forest 
ebolavirus(1978a; Georges et al, 1999; Heymann et al, 1980; Towner et al, 2008). During 
these isolated but severe outbreaks, case fatalities between 20%-90% have been reported for 
the various species of filoviruses. Reston ebolavirus (REBOV) was discovered following an 
outbreak in Reston, Virginia, USA when animal handlers contracted the virus from macaques 
imported from Phillipines(Jahrling et al, 1990). While it caused severe disease and near 
100% lethality in the infected macaques, the animal handlers recovered from the outbreak 
without any apparent symptoms even though they had seroconverted, suggesting that this 
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species may not cause disease in humans. More recently, REBOV has been isolated from a 
swine population in the Philippines, suggesting the zoonotic potential of filoviruses(Barrette 
et al, 2009). However limited data are currently available on the natural host range of 
filoviruses, with some studies indicating that several species of fruit bats maybe the natural 
reservoir(Leroy et al, 2005; Towner et al, 2009). A recent study reported the isolation of a 
genetically distinct filovirus called Lloviu virus from insectivorous bats in Cueva del Lloviu, 
Spain lending further support to the notion that bats may serve as the natural reservoir for 
filoviruses(Negredo et al, 2011). Of the different filoviruses identified so far, the Zaire 
ebolavirus (ZEBOV) has been the most virulent, with the highest fatality rates (~90%) 
among all outbreaks reported(Bwaka et al, 1999; Heymann et al, 1980). The zoonotic nature, 
rapid and severe disease progression, and the lack of vaccines or therapeutics make 
filoviruses a public health hazard and a potential agent of bioterrorism, following reports that 
suggested that filoviruses may spread through aerosol route in addition to direct contact with 
bodily fluids of infected animals(Alves et al, 2010; Leffel & Reed, 2004). One of the reasons 
attributed to the severity of filoviral infections is effective shut down of innate and adaptive 
immune response by virus encoded immune antagonists. It is extremely important to 
understand the molecular mechanisms of how these viral proteins mediate immune evasion, 
in order to develop strategies for designing antivirals. 
 
2.2 Filovirus pathogenesis 
Severe filoviral infections are characterized by early non-specific symptoms that 
progress to sever hemorrhagic fever during the final stages of the disease. The incubation 
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period ranges anywhere between a few days to about 2 weeks after which the patients start to 
develop symptoms such as fever, severe arthralgia and myalgia, nausea, vomiting, diarrhea, 
abdominal pain and maculopapular rashes, especially in the torso, indicative of dysregulation 
of coagulation and blood clotting mechanisms(Feldmann & Geisbert, 2011; Georges et al, 
1999; Heymann et al, 1980). Infections are characterized by complete lack of innate immune 
responses, especially interferons and subsequent dysregulation of the adaptive immune 
responses. Further symptoms that develop include severe liver and kidney failure, massive 
internal hemorrhage in multiple organs, delirium and coma resembling septic shock 
syndrome(Hartman et al, 2010; Kortepeter et al, 2011). Both EBOV and MARV have broad 
host tropism, and replicate to high levels in key immune cells such as monocytes, 
macrophages, dendritic cells and hepatocytes. This results in severe dysregulation of pro-
inflammatory cytokine release late during infection, causing massive inflammation and 
cytokine storms, which result in tissue and organ damage(Takada, 2012). Thus the early 
shutdown of innate immunity and the resulting dysregulation of adaptive immunity result in 
unchecked viral replication. 	  
2.3 Filovirus replication cycle  
Filoviruses are named after their signature pleomorphic, filamentous appearance in electron 
micrographs, often forming circular or shepherd’s hook shaped virions(Baskerville et al, 
1985; Ellis et al, 1978) (Figure 2-1A). Filoviruses belong to the order Mononegavirales; they 
have a single-stranded negative sense RNA genome. The 19-kilobase genome encodes seven 
structural proteins, nucleoprotein (NP), viral protein 35 (VP35), VP40, glycoprotein (GP), 
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VP30, VP24 and Large protein (L) (Figure 2-1B). The genome organization is most similar 
to rhabdoviruses and paramyxoviruses(Elliott et al, 1985; Feldmann & Geisbert, 2011). 
Conserved polyadenylation sites at the 3’ and 5’ UTR regions of the filoviral genome act as 
transcriptional start and stop sites(Sanchez et al, 1993). In addition the secondary structure at 
the 5’ UTR of the genome regulates transcriptional initiation, replication and nucleocapsid 
formation(Crary et al, 2003). The nucleocapsid in the virion is composed of the RNA 
genome bound to NP and VP30(Becker et al, 1998; Welsch et al, 2010). The major and 
minor matrix proteins, VP40 and VP24 make up virion which is enclosed in a host-derived 
lipid bilayer membrane, which is embedded with trimeric spikes formed by the envelope 
protein, GP. Four proteins - NP, VP30, VP35 and the RNA-dependent RNA polymerase L 
form the viral polymerase complex(Elliott et al, 1985; Ellis et al, 1978) 
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Figure 2-1. Filoviral genome organization.  
(A) Filoviruses have a characteristic filamentous appearance as observed in this 
representative electron micrograph of the ebolavirus virion (Photo credit to Frederick 
Murphy). 
(http://www.cdc.gov/ncidod/dvrd/spb/mnpages/dispages/Fact_Sheets/Ebola_Fact_Booklet.pd
f). (B) Filoviruses have a single stranded, anti-sense, non-segmented, genome of about 19 
kilobases, encoding for seven structural proteins indicated. 
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Cell entry is the first step in the filovirus replication cycle. Filoviruses exhibit broad tissue 
tropism – they gain entry into the host through a wide variety of cell types including dendritic 
cells, monocytes, macrophages, epithelial cells, hepatocytes, and endothelial cells(Bosio et 
al, 2003; Feldmann & Geisbert, 2011). Hence it is likely that the viral envelope protein GP 
mediates interactions with a variety of cell surface receptors and host factors in order to gain 
entry into host cells. Although receptor specificity for filoviruses in different cell types is 
poorly understood, recent studies suggest that viral entry is mediated by GP interactions with 
the T-cell immunoglobulin mucin domain-1 (TIM-1) receptor in epithelial cells(Hunt et al, 
2012; Kondratowicz et al, 2011). The C-type lectin receptors (CLRs), L-SIGN and DC-SIGN 
are also thought to be receptors involved in filoviral entry. It has been shown that the 
expression of these C-type lectin receptors enhances filvorial entry in some cell types(Marzi 
et al, 2007; Matsuno et al, 2010). The GP protein is cleaved by furin protease post-
translationally into two subunits called GP1 and GP2, which are linked through disulfide 
bonds(Volchkov et al, 1998). The pre-fusion conformation of EBOV GP was structurally 
characterized by using a truncated form of GP bound to KZ52 antibody, which was 
previously isolated from a human survivor in the Democratic Republic of Congo(Lee et al, 
2008; Maruyama et al, 1999) (Figure 2-2-A). The GP1 and GP2 subunits are involved in 
extensive protein-protein interactions to form the trimeric conformation. The EBOV GP has 
been proposed to undergo conformation changes to mediate viral and host membrane fusion 
by an unknown trigger which results in the GP2 subunit forming a six helix-bundle which 
represents the post-fusion conformation, and this conformation has also been structurally 
characterized(Malashkevich et al, 1999) (Figure 2-2B). This architecture of the GP2  
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Figure 2-2. Structure of filoviral GP protein.  
(A) Prefusion conformation of the EBOV GP trimer made of the GP1 (blue) and the GP2 
(yellow) subunits which are disulfide linked and bound by the human antibody KZ52 
(magenta) at the base of the trimeric region (PDB 3CSY)(Lee et al, 2008). (B) Fusion active 
conformation of the GP2 (yellow) subunit of EBOV shows a six-helix bundle similar in 
architecture to other viral membrane fusion proteins (PDB 2EBO)(Malashkevich et al, 1999). 
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subunit resembles that of other viral membrane fusion proteins such as the influenza virus 
and HIV. The GP protein of filoviruses is heavily glycosylated and the mucin-like domain 
and the glycan cap may mediate interactions with the CLRs(Lee et al, 2008; Lee & Saphire, 
2009; Olal et al, 2012). However it is also likely that the mucin-like domain plays a role in 
enhancing adherence to host cells by interacting with cell-surface adhesion molecules, but 
may not play a direct role in the entry mechanism. Internalization of the virus particle into 
endosomes occurs predominantly through macropinocytosis, among other mechanisms, but 
both caveolin-dependent and clathrin-dependent endocytosis have been proposed as 
mechanisms of viral internalization(Aleksandrowicz et al, 2011; Hunt et al, 2012; Nanbo et 
al, 2010) (Figure 2-3). It has been shown that the tyrosine kinase receptor Axl, enhances 
EBOV uptake into cells, but other studies have shown that this is due to enhanced 
macropinocytosis in Axl expressing cells and not due to receptor mediated cell 
entry(Brindley et al, 2011; Hunt et al, 2011). It is currently unknown what the predominant 
mechanism of internalization is, and whether there is cell-type specificity associated with this 
process. It is also unknown whether multiple mechanisms may be at play in the same cell-
type. More recently, multiple studies have reported that the host protein Niemann-Pick C1 
(NPC1) protein may play an important role in the entry process(Carette et al, 2011; Cote et 
al, 2011). NPC1 is a host protein and primarily found on endosomal and lysosomal 
membranes, and plays a role in cholesterol homeostasis. This study showed that cells lacking 
NPC1 showed resistance to EBOV entry. This study was also able to show that it was NPC1 
expression and not its function in lipid transport that led to this phenotype(Carette et al, 2011; 
Cote et al, 2011). However the exact mechanism by which NPC1 mediates EBOV entry is 
still unknown.  
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Figure 2-3. Filoviral replication cycle.  
Filoviruses are enveloped viruses and gain entry into cells through multiple receptors whose 
identities and mechanisms are not clearly known. Filoviruses are thought to undergo 
macropinocytosis and endosomal processing upon entry. Once fusion occurs, the negative 
sense, single-stranded genome is released into the cytoplasm of the host cell, where it 
undergoes replication and transcription by the viral polymerase complex. The matrix and 
nucleoprotein complex first forms filamentous assemblies, into which the other viral proteins 
are recruited. These assemble at the plasma membrane through lipid rafts and viral budding 
is mediated by hijacking a number of host protein complexes (Figure adapted from Fields 
Virology). 
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Upon viral entry, the GP protein undergoes proteolytic processing by the cathepsin L and B 
enzymes, in the acidic environment of the endosome, resulting in membrane fusion and 
release of the RNA genome into the cytosol of the host cell(Bale et al; Brecher et al; Hunt et 
al, 2012). Cathepsin L cleaves off the mucin-like domain and the glycan cap of the filoviral 
GP, followed by further processing by Cathepsin B, which results in the fusion-ready state of 
GP. The exact nature or conformation of the functionally active GP is currently unknown. In 
addition to the full length GP protein that EBOV encodes, as a result of transcriptional frame 
shifting, it also encodes a truncated version of GP called soluble GP (sGP)(Mehedi et al, 
2011). This soluble form of GP has been proposed to function as a decoy for the host 
immune responses during filoviral infections(Falzarano et al, 2006). Since filoviruses are 
negative sense single-stranded RNA viruses, the viral RNA-dependent RNA polymerase 
(RdRp) first transcribes the negative sense RNA genome into the positive sense messenger 
RNAs before viral protein synthesis can occur. In the filoviral genome, short regions of the 
stop site of the upstream gene overlap with regions of the start site of the downstream gene. 
The arrangement of genes from the 3’ to the 5’ end of the viral genome in addition to the cis-
acting elements flanking each gene serves as a regulatory mechanism of gene 
expression(Crary et al, 2003; Sanchez et al, 1993). There is attenuated transcription of the 
genes that are farther from the 3’ end of the genome, which means NP is the most highly 
expressed viral protein, whereas the viral polymerase L is the least expressed. The amount of 
NP transcribed regulates the switch from transcription to genome replication in infected cells. 
Genome replication involves synthesis of the full-length positive sense RNA strand, which 
can then act as a template to make the negative sense genomic RNA. The viral 
replication/transcription complex formed by NP, VP35, VP30 and L then synthesizes both 
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viral mRNA and positive sense template RNA for genome replication. The newly 
synthesized proteins, in particular NP, mediate the formation of new nucleocapsid. Filoviral 
NP has been reported to form helical assemblies with cellular RNA and form inclusion 
bodies when expressed in insect cells, similar to what is observed in filovirus infected cells, 
although VP30 and L are also recruited to the nucleocapsid. Additionally both matrix 
proteins VP40 and VP24 have been shown to play important roles in viral particle assembly 
mediated by interactions with a multitude of host proteins, the identities of which are not yet 
fully understood(Hartlieb et al, 2007; Huang et al, 2002).  
 
VP40 is the major matrix protein and plays a very important structural role in 
maintaining the integrity of the virion. Like other matrix proteins, VP40 has been shown to 
interact with lipids and host cell membranes to mediate morphogenesis and budding of the 
virus, and also has been shown to important for the regulation of viral replication and 
transcription(Hoenen et al, 2010a; Hoenen et al, 2010b). Previous structural studies on 
EBOV VP40 have resulted in the crystal structures of both free (Figure 2-4A) and RNA-
bound forms (Figure 2-4B) of VP40 in the monomeric and octameric state 
respectively(Dessen et al, 2000; Gomis-Ruth et al, 2003; Ruigrok et al, 2000). These 
structural studies collectively suggest that EBOV VP40 has a distinct fold when compared to 
previously characterized matrix proteins from viruses belonging to the Mononegavirales 
order. VP40 contains two structurally similar N- and the C-terminal domains, both consisting 
of beta sheets packed on the lateral surface by an alpha helix. The C-terminal domain 
consists of a highly hydrophobic surface, which may be involved in interactions with lipid 
membranes. The RNA-bound VP40 also assembles into an octamer by undergoing two major 
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conformational changes at both the N and the C-terminal domains stabilized by the RNA 
contacts made(Dessen et al, 2000; Gomis-Ruth et al, 2003; Ruigrok et al, 2000). These 
octameric assemblies of EBOV VP40 may recruit additional host proteins, such as Tsg101 at 
the plasma membrane of infected cells(Urata et al, 2007).  
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Figure 2-4. Crystal structures of EBOV VP40.  
(A) ZEBOV VP40 (blue) consists of structurally similar N and C-terminal domains of beta-
sheets packed against an alpha-helix. (B) VP40 (blue) oligomerizes into ring-shaped 
octamers upon RNA (orange) binding (PDB 1H2C)(Gomis-Ruth et al, 2003). 
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VP24 is the minor matrix protein, which in addition to being a structural protein in the virion 
serves to regulate nucleocapsid formation, viral replication and transcription and also plays 
an important role in viral morphogenesis and budding(Noda et al, 2007; Watanabe et al, 
2007). In addition to all these functions recent studies have uncovered a novel mechanism by 
which VP24 inhibits type I IFN mediated signaling and thus serves as an immune antagonist. 
These studies support a model in which VP24 interacts with the karyopherin-alpha family of 
host proteins, which play an important role in trafficking activated transcription factors called 
STATs into the nucleus. VP24 is able to inhibit STAT accumulation in the nucleus by 
interacting with the karyopherin proteins(Mateo et al, 2010; Reid et al, 2006; Reid et al, 
2007)(Figure 2-6). This was demonstrated by intracellular localization studies, which showed 
that in the presence of ZEBOV VP24, GFP-tagged, phosphorylated STAT1 accumulated in 
the cytoplasm of Vero cells. Recent structural studies on VP24 has resulted in crystal 
structures of REBOV and SEBOV VP24 proteins, which show that the VP24 protein has a 
novel triangular pyramid fold, made of both alpha helices and beta sheets (Figure 2-5A and 
B)(Zhang et al). Mapping of residues from REBOV and SEBOV onto the structure reveals 
that some surfaces of the pyramidal fold are conserved while others are not. The functional 
significance of these differences is still unknown. Taken together, these data support a novel 
mechanism, where VP24 inhibits IFN mediated signaling and antiviral gene production by 
interacting with karyopherin proteins to inhibit the nuclear translocation of activated STAT 
proteins. 
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Figure 2-5. Crystal structures of EBOV VP24.  
A novel pyramidal fold of VP24 protein from (A) Reston EBOV (cyan representation) and 
(B) Sudan EBOV (red representation) (PDBs 4D9O and 3VNE)(Zhang et al). 
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VP30 plays a very important role in capsid formation and regulates the transcriptional 
activity of the replication complex through interactions with specific RNA secondary 
structures in the transcriptional start sites of the viral genomic RNA(Weik et al, 2002). It has 
also been shown that phosphorylation state of VP30 modulates its activity in transcription, 
with hyper-phosphorylation leading to transcriptional inhibition. A cluster of serine residues 
in the N-terminus of VP30 have been shown to be functionally important phosphorylation 
sites, as mutation of these residues to phosphomimetic aspartate residues downregulated the 
transcriptional activity of VP30 in a minigenome assay(Modrof et al, 2002). Recent structural 
studies on VP30 have resulted in crystal structure of the C-terminal domain of VP30, which 
is a dimer in solution (Figure 2-6). In addition, full length VP30 has also been shown to form 
hexamers both in vitro and in vivo. These studies showed that EBOV VP30 plays an essential 
role in transcriptional activation, likely through stabilization of the viral mRNA(Hartlieb et 
al, 2007). 
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Figure 2-6. Crystal structure of EBOV VP30.  
The C-terminal domain of EBOV VP30 shows a six-helix core with the seventh helix 
forming the dimeric interface for the head to head packing of the two monomers (depicted as 
magenta and green cartoon representation) (PDB 2I8B)(Hartlieb et al, 2007). 
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VP35 plays multiple critical roles by functioning as a co-factor in the viral replication 
complex and in mediating immune evasion. EBOV VP35 was identified as a type I IFN 
antagonist using a recombinant influenza virus in which the NS1 gene was deleted and 
replaced by each filoviral gene in growth complementation assays. Among the filoviral 
genes, only VP35 had the ability to rescue the growth of the NS1-deleted virus in 293T 
cells(Basler et al, 2000). VP35 able to was suppress the activation of IFN-beta promoter and 
IFN-beta production in 293T cells by Sendai virus infection or poly I:C transfection 
suggesting a potential role for it in immune evasion, similar to influenza NS1(Basler et al, 
2000). VP35 was also proposed to be an RNA binding protein, based on sequence alignments 
with influenza NS1 which suggested that a short stretch of residues in ZEBOV VP35, which 
includes R305, K309, and R312 in the C-terminal domain, were conserved in NS1(Hartman 
et al, 2004). These residues were are important for RNA binding in NS1 protein, and 
mutation of these residues to alanine also resulted in diminished RNA binding and IFN 
inhibition in VP35, suggesting that they may have a potential role in IFN antagonist function 
of VP35 through which it can potentially inhibit RIG-I like receptor mediated IFN-beta 
promoter activation(Cardenas et al, 2006; Hartman et al, 2004). Using C-terminal truncation 
mutants of ZEBOV VP35, subsequent studies showed that the deletion of last 40 residues of 
VP35 was enough to disrupt its IFN antagonist functions, suggesting that the IFN inhibitory 
function was localized to the C-terminus of the protein(Hartman et al, 2004). We recently 
solved the crystal structure of the C-terminal IFN inhibitory domain (IID) of Zaire (PDB 
3FKE) (Figure 2-7B) and Reston VP35 IID (PDB 3L2A) (Figure 2-7C) in the free form and 
Zaire VP35 IID in the  
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Figure 2-7. Crystal structures of EBOV VP35 IID.  
(A) ZEBOV VP35 is a two domain proteins with the coiled-coil oligomerization motif (blue) 
at the N-terminus and the interferon inhibitory domain at the C-terminus (orange). Residue 
numbering is for ZEBOV VP35. (B) Cartoon representation of structure of ZEBOV VP35 
IID in orange (PDB 3FKE) revealed a novel dsRNA binding protein fold with an alpha 
helical and a beta sheet subdomain(Leung et al, 2009). (C) Cartoon representation of 
structure of REBOV VP35 IID in blue (PDB 3L2A) shows that the overall fold of IID is 
highly conserved between the two proteins(Leung et al, 2010b). 
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dsRNA-bound form (PDB 3L25 and 3L26)(Leung et al, 2009; Leung et al, 2010a; Leung et 
al, 2010b). Subsequently the REBOV VP35 IID-dsRNA structure was solved by others (PDB 
3KS8)(Kimberlin et al, 2010). Both ZEBOV and REBOV VP35 IID form a novel dsRNA-
binding fold consisting of an alpha helical subdomain and a beta sheet subdomain. This is 
structurally distinct from the canonical dsRNA binding domains which consists of a αβββα 
fold(Masliah et al, 2012). The ZEBOV and REBOV VP35 IID structures had near identical 
structures(Leung et al, 2010b). EBOV VP35 IID contains two patches of basic residues, the 
first basic patch (FBP), including residues K222, R225, K248, and K251 is located on the a-
helical subdomain of IID (Figure 2-8B) whereas the central basic patch (CBP), consisting of 
residues R305, K309, R312, K319, R322 and K339, is located on the beta-sheet subdomain 
of IID (Figure 2-8A)(Leung et al, 2009). In Reston VP35 IID the corresponding CBP 
residues consist of R301, K308, R311 and K328, which are equivalent to the R312, K319, 
R322 and K339 residues in ZEBOV VP35. Through biochemical characterization and 
mutational analysis we found that the residues in the FBP were critical for ZEBOV VP35-NP 
interactions, and alanine substitutions of the FBP residues resulted in loss of NP binding as 
assessed by in vitro pull-down assays(Prins et al, 2010). This loss of NP binding was 
correlated to defective replication complex, since alanine substitutions of FBP residues of 
VP35 resulted in loss of viral replication activity as assessed by a minigenome assay(Prins et 
al, 2010). This suggests a critical role for ZEBOV VP35-NP interactions in viral replication 
complex formation. The ZEBOV VP35-dsRNA bound structure showed that the CBP 
residues are involved in direct interactions with the phosphodiester backbone of the dsRNA 
through direct and water-mediated hydrogen bonds. Lack of base-specific contacts suggested 
that  
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Figure 2-8. Functionally important residues in ZEBOV VP35 IID.  
(A) Central basic patch residues in the beta sheet subdomain R305, K309, R312, K319, R322 
and K339 are highlighted as sticks. (B) First basic patch residues (FBP) in the alpha helical 
subdomain K222, R225, K248 and K251 are highlighted as sticks (PDB 3FKE)(Leung et al, 
2009). 
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VP35 binds dsRNA in a sequence independent manner. In addition to the backbone contacts, 
ZEBOV VP35 can also interact with the blunt-ends through conserved hydrophobic residues 
such as F239 and I340. Together, this data suggests that the central basic patch (CBP) 
residues and surrounding basic residues contribute to dsRNA binding and play an important 
role in VP35 mediated IFN antagonism.   
Once the host immune system has been successfully evaded to facilitate viral protein 
production and viral genomic replication, new nucleocapsids are assembled with the viral 
genomic RNA and these viral components are transported through the host golgi and trans-
golgi pathway to the cell surface, in preparation for viral egress. The host protein complex 
called endosomal sorting complex required for transport (ESCRT)-1 has been implicated in 
forming multivesicular bodies carrying viral proteins, that are involved in budding and 
egress. The viral GP undergoes glycosylation and processing by getting transported through 
the host golgi apparatus and is expressed on the cell surface(Dolnik et al, 2010; Silvestri et al, 
2007). New virions are assembled near the host cell membrane, mediated by the transport 
and localization of viral proteins embedded in lipid raft-like structures, and these virions then 
undergo cell egress, acquiring the GP-decorated host membrane in the process (Figure 2-2).  
 
2.4 Differences between ebolavirus and marburgvirus  
 
 In order to develop panfiloviral therapeutics or vaccines, it is important to gain 
insights into the differences and similarities between ZEBOV and MARV. Despite the 
overall similarities in genome size and organization, virion structure and disease 
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characteristics, EBOV and MARV have important and interesting differences not only in 
host tropism, mechanisms of viral entry, viral replication and transcription strategies, but also 
in mechanisms of immune evasion(Basler & Amarasinghe, 2009; Enterlein et al, 2009; 
Feldmann et al, 1999; Hartman et al, 2008; Mehedi et al, 2011; Mittler et al, 2011; 
Muhlberger et al, 1998; Muhlberger et al, 1999; Valmas & Basler, 2011; Valmas et al, 2010). 
At the level of genome organization, several differences have been observed between 
ZEBOV and MARV. For example, the filoviral genome has short specific sequences at the 
untranslated regions (UTRs) of both the 5’ and 3’ ends(Enterlein et al, 2009). These short 
stretches of RNA regulate transcriptional initiation, termination, replication and genome 
encapsidation. Previous work has shown that a single stem-loop secondary structure at the 3’ 
UTR of NP in the ZEBOV genome regulates VP30 mediated transcriptional initiation(Weik 
et al, 2002). Similar studies of the MARV genome have shown that the RNA secondary 
structure at the 3’ UTR of NP is substantially different, consisting of two stem-loop regions. 
While the first stem-loop structure is also found in the ZEBOV 3’ UTR, the second stem-
loop is MARV genome specific and is responsible for transcription initiation that occurs 
independent of VP30 protein in MARV. This is consistent with recent studies that were 
aimed at developing an artificial minigenome model to study filoviral transcription and 
replication, which revealed that EBOV and MARV had distinct nucleocapsid requirements. 
While only NP, VP35 and L were required and sufficient to carry out both genome 
replication and transcription in the case of MARV, EBOV required four nucleocapsid 
proteins – NP, VP35, L and VP30 to carry out transcription(Muhlberger et al, 1998; 
Muhlberger et al, 1999). Moreover, if one of the three proteins NP, VP35 or L was 
exchanged with the heterologous protein, genome replication or transcription did not occur, 
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suggesting significant differences in nucleocapsid formation. Transcriptional profiling and 
bioinformatics analysis of human hepatocytes infected with EBOV and MARV suggest that 
the viruses are similar in their ability to regulate TLR, Type I IFN, and PKR mediated 
signaling pathways. Notably, both EBOV and MARV were able to regulate antiviral ISGs 
and inflammatory cytokine production in hepatocytes(Kash et al, 2006). However, when 
these cells were analyzed for the phosphorylation states of STAT1 and STAT2, MARV 
infected cells, but not EBOV infected cells, showed significant reduction of STAT 
phosphorylation. Given that both EBOV and MARV were able to inhibit the production of 
ISGs, these data suggest that there may be distinct underlying immune evasion mechanisms. 
Unlike EBOV VP24, MARV VP24 does not participate in inhibiting type I IFN signaling. 
Instead recent studies have shown that MARV VP40 can inhibit the JAK-STAT pathway by 
direct inhibition of phosphorylation of STAT proteins by interacting with the JAK1 and 
TYK2 kinases(Valmas & Basler, 2011; Valmas et al, 2010). Thus MARV VP40, in addition 
to its role in the virion as a matrix protein, is able to inhibit not only type I IFN signaling but 
also type II IFN signaling, because both these IFNs use common Janus kinases to activate the 
downstream transcription factors STAT and IRF-9. MARV VP40, by inhibiting this signal 
transduction cascade upstream of phosphorylation of STATs and IRF-9, can inhibit the 
transcription of both ISGs and genes under the GAS promoter. 
2.5 Conclusions 
Key differences in genome organization, transcription, replication, host entry, viral 
tropism, and immune evasion mechanisms of the viral proteins suggests that MARV and 
EBOV are distinct viruses, even though they retain some overall similarities. These 
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observations motivate our undertaking studies that aim to understand differences in 
structural, functional and mechanistic aspects of filoviral proteins, especially VP35, in order 
to characterize unique aspects of these two viruses. Most of the mechanistic studies 
addressing immune evasion by filoviruses have been done in EBOV, particularly in ZEBOV, 
highlighting the lack of understanding of how the corresponding proteins in MARV function. 
This underscores the need for studying MARV proteins in order to develop strategies to 
target common mechanisms that these two deadly filoviruses may use for immune evasion. 
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3.1 Introduction 
VP35 is a critical protein and plays multiple roles in the viral replication cycle(Basler 
& Amarasinghe, 2009). It functions as a structural protein in the virion, mediates 
transcription and replication as an integral part of the viral replication complex, and functions 
as an immune antagonist through multiple mechanisms. VP35 has an N-terminal 
oligomerization domain and a C-terminal interferon inhibitory domain (IID). Structural and 
biochemical work from our lab identified VP35 IID as a novel RNA binding fold that 
specifically recognizes dsRNA in a sequence independent fashion. These studies also 
identified a number of key basic residues that mediate both the dsRNA binding and NP-
binding/replication functions of VP35. In order to further understand the mechanisms by 
which VP35 mediates immune evasion and to understand the structural basis for dsRNA 
binding, we conducted structural studies on VP35 IID-dsRNA complex. 
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3.2 Materials and methods 
 
Cloning, protein expression and purification. The coding region of ZEBOV 
(Mayinga strain), REBOV VP35 IID, full length RIG-I (residues 1-925) and RIG-I C-
terminal domain (residues 792-925) was subcloned using Nde1 and BamH1 restriction 
enzyme sites into a modified pET15b expression vector, downstream of a MBP fusion tag 
and a TEV cleavage site. Using primers containing the desired mutations, mutant ZEBOV 
VP35 IID constructs were generated by overlap PCR, digested with restriction enzymes 
Nde1 and BamH1 and ligated into the same pET vector described above. PCR and DNA 
sequencing subsequently confirmed the presence of mutations. All the constructs mentioned 
above were expressed as MBP-fusion proteins by culturing transformed BL21(DE3) cells in 
LB media at 37°C until an OD600 of 0.7. Cells were then chilled in ice and induced with 
0.5mM IPTG and cultured overnight at 18°C. Cells were harvested by centrifugation at 
10,000 g at 4°C for 10 minutes. Harvested cells were resuspended in lysis buffer containing 
25mM sodium phosphate (pH 7.0), 1M NaCl, 5mM β-mercaptoethanol and a protease 
inhibitor cocktail, flash frozen using liquid nitrogen, and stored at -80°C. Cells were thawed 
and lysed using an Emulsiflex-C5 homogenizer (Avestin) and clarified by centrifugation at 
30,000 g for 30 minutes. The supernatant was then purified using a combination of affinity, 
cation exchange and size exclusion chromatographic columns (GE Healthcare). The MBP 
fusion tag was cleaved prior to final purification by using tobacco etch virus (TEV) protease. 
Protein purity was assessed by SDS-PAGE followed by Coomassie blue staining.   
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Crystallization, data collection and processing. Initial crystallization trials with 
purified Zaire VP35 IID K319A/R322A were performed using standard Hampton sparse-
matrix screens using hanging-drop vapor diffusion methods and subsequent optimization of 
hits was done with in-house prepared chemicals. Single, plate shaped crystals of VP35 IID 
K319A/R322A was obtained in well solution containing 0.1M Bis-Tris pH 6.75, 0.2M 
ammonium sulfate, and 28% PEG 3350 at protein concentration of 7 mg/mL. Crystals were 
soaked in well solution containing 10% and 25% glycerol before plunge-freezing in liquid 
nitrogen. Diffraction data was collected at the Advanced Light Source (ALS), beamline 4.2.2 
and Advanced Photon Source (APS), beamline 19 ID. 180 frames were collected at a crystal 
to detector distance of 125 mm using an oscillation range of 1°.  
 
Diffraction data were indexed, scaled and merged using HKL-3000 (Otwinowski & 
Minor, 1997). Intensities were converted to structure factors using CCP4 suite. Phases for 
ZEBOV VP35 IID K319A/R322A mutant and ZEBOV VP35 IID-dsRNA complex structures 
were determined using molecular replacement with chain B from wildtype ZEBOV VP35 
IID crystal structure (3FKE) as search model. Molecular replacement was performed using 
MOLREP in the CCP4 suite, and the resulting model was refined using REFMAC5 
(Murshudov et al, 1997). Water addition and manual model building was performed using 
Coot (Emsley & Cowtan, 2004). TLS parameters were refined using the TLMSD server 
(Painter & Merritt, 2006).  Final validation was performed using MOLPROBITY server 
(Chen et al, 2010).  
 
 
  
 
79 
 
3.3 Structure of EBOV VP35 IID-dsRNA complex 
 
We solved the crystal structure of ZEBOV VP35 IID in complex with 8bp dsRNA using 
both native (3L25) and selenomethionine (SeMet) labeled protein (3L26). Both structures 
were solved using molecular replacement with the ZEBOV VP35 IID structure (PDB 3FKE) 
as the search model. Since the SeMet dataset was the higher resolution dataset, we used this 
for further processing and analysis. For the SeMet dataset, we observed four molecules of 
VP35 IID and one molecule of 8bp dsRNA, with a two fold non-crystallographic symmetry, 
where two of the VP35 IID molecules (chains A and B) are symmetry related to the other 
two VP35 IID molecules (chains C and D) (Figure 3-1). The overall structure of VP35 IID is 
very similar compared to the free structure, suggesting that the molecule does not undergo a 
conformational change during dsRNA binding. Additionally, majority of the contacts are 
with dsRNA backbone suggesting that VP35 IID recognizes the A form dsRNA helix in a 
sequence independent manner. 
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Figure 3-1. Structure of ZEBOV VP35 IID in complex with 8bp dsRNA.  
Four molecules of ZEBOV VP35 IID (orange) binds to one molecule of 8bp dsRNA (green) 
backbone and blunt ends. Of the four molecules, which binds dsRNA, two are involved 
predominantly in VP35-VP35 interactions, while the other two are involved in VP35-dsRNA 
interactions (PDB 3L26)(Leung et al, 2010).  
  
 
81 
3.4 CBP residues are involved in VP35-VP35 and VP35-dsRNA 
interactions 
 
The dsRNA-bound structure of ZEBOV VP35 IID (Figure 3-1) confirms the role of CBP 
residues in dsRNA binding, as these residues make direct contacts with the phosphate 
backbone of dsRNA (Figure 3-2A). For example, the side chain NH1 and NH2 atoms of 
R312 contact the dsRNA U5 O1P and O2P atoms through hydrogen bonds. Similarly the side 
chain NH2 atom of R322 hydrogen bonds with the C7 O2P and G6 O1P atoms of the 
dsRNA. Additional residues that mediate VP35-dsRNA interactions include T237, S272, 
Q274, K309, S310 and I340. In addition to these contacts with dsRNA, the CBP residues 
R312, R322 and K339 are also involved in salt bridges with the acidic residues such as E262, 
E269 and D271 of the neighboring VP35 molecule (Figure 3-2B). Hence the CBP residues 
are not only important for dsRNA binding but also are part of the protein-protein interaction 
interface. Consistent with the structure mutation of any of the CBP residues, especially R312, 
R322 and K339 results in complete loss of dsRNA binding as demonstrated by in vitro 
isothermal titration calorimetry experiments (Figure 3-2C). The VP35 IID molecule also 
interacts with the dsRNA blunt ends by hydrophobic stacking of residues such as F239, I340 
and Q274 and thus covers the ends of dsRNA (Figure 3-3). This is very similar to the 
recognition mode of RIG-I. This structural data suggests that ZEBOV VP35 IID can mimic 
the RNA binding mode of RIG-I and thus compete with it for dsRNA binding. We also 
solved the crystal structures of the CBP mutants R312A, K339A and K319A/R322A (Figure 
3-4) and were able to show that mutations of these residues do not cause overall changes in  
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Figure 3-2. CBP residues are important for VP35-VP35 and VP35-dsRNA interactions. 
(A) ZEBOV VP35 IID binds to dsRNA (green sticks) through the basic residues contain 
within the CBP such as R312, K339 and R322 (orange sticks). (B) The CBP residues are also 
involved in protein-protein interactions with acidic residues such as E262, E269 and D271 
(PDB 3L26). (C) ITC data of ZEBOV VP35 IID WT, R312A, R322A and K339A (from left 
to right) shows that mutation of CBP residues to alanine, leads to loss of dsRNA binding in 
vitro (Leung et al, 2010). 
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Figure 3-3. VP35 IID caps the blunt-ends of dsRNA. 
ZEBOV VP35 IID in addition to binding the dsRNA backbone interacts with the blunt ends 
of dsRNA mediated by the side chain of residues F239, I340 and Q274 (PDB 3L25)(Leung et 
al, 2010). 
 
 
  
 
84 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-4. Structure of CBP mutants of ZEBOV VP35 IID.  
Representative crystals of ZEBOV VP35 IID (A) R312A, (B) K339A and (C) 
K319A/R322A. The electrostatic surface (red, white and blue represent negative, neutral and 
positive electrostatic potentials respectively) representation of ZEBOV VP35 IID (range -10 
to +10 kT), shows the loss of the positive charge on the surface of the molecule highlighted 
by dotted green circles for each of the three CBP mutants (D) R312A (PDB 3L27), (E) 
K339A(PDB 3L28) and (F) K319A/R322A(PDB 3L29)(Leung et al, 2010; Prins et al, 2010). 
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the structure, but results in changes in the surface electrostatics of the molecule, which 
affects dsRNA binding.  
 
 In order to assess the role of dsRNA binding and its contribution to IFN antagonism 
by preventing RIG-I like receptors from binding to viral RNA PAMPs, we used a specific 
nuclear magnetic resonance (NMR) experiment called heteronuclear single quantum 
coherence (HSQC) experiment to record the spectra of 1H, 15N labeled ZEBOV VP35 IID in 
the presence and absence of RIG-I and dsRNA. First the experiment was done with only 
ZEBOV VP35 IID (black spectrum in Figure 3-5A,B and C). Upon addition of in-vitro 
transcribed (IVT) 8bp dsRNA, the intensities of the individual chemical shifts drop relative 
to the ZEBOV VP35 IID only spectrum, as a result of increased molecular size and slower 
tumbling time of the ZEBOV VP35 IID-dsRNA complex in solution (Figure 3-5B). Upon 
addition of purified RIG-I C-terminal domain (residues 792-925), the intensities did not 
result in increase in peak intensities, suggesting that ZEBOV VP35 IID can compete with 
RIG-I for dsRNA binding in solution. This observation is not a result of direct interactions 
between ZEBOV VP35 IID and RIG-I as addition of RIG-I to ZEBOV VP35 IID in the 
absence of dsRNA did not cause any chemical shift perturbations and showed peak 
intensities that were similar relative to the ZEBOV VP35 IID only spectrum. Our 
collaborators then assessed the effect of ZEBOV VP35 on RIG-I and RNA induced IFN-β 
promoter activation using in vivo assays (Figure 3-5E). These studies were able to show IVT 
8-bp dsRNA or hairpin RNA transfection into 293T cells along with a plasmid encoding 
RIG-I protein, resulted in the activation of the IFN-β promoter as assessed by the luciferase  
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Figure 3-5. ZEBOV VP35 IID competes with RIG-I for dsRNA binding.  
HSQC-NMR spectra of ZEBOV VP35 IID (black) after addition of (A) IVT-8bp dsRNA 
(red), (B) IVT-8bp dsRNA and RIG-I (green) and (C) RIG-I (blue). The peak for R312 
residue is shown in the box for each of the three spectra. (D) The peak intensities of every 
residue from (A), (B) and (C) are plotted relative to the ZEBOV VP35 IID only spectra 
(black dotted line). (E) IFN-beta reporter activity assay induced by transfection of RIG-I and 
different RNA ligands in the presence and absence of ZEBOV VP35 (Leung et al, 2010).  
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reporter gene expression (Figure 3-5E). In contrast, when a plasmid encoding for ZEBOV 
VP35 was also transfected, the reporter gene expression was significantly less, suggesting 
that ZEBOV VP35 is able to inhibit IFN-β promoter activity induced as a result of RNA 
recognition by RIG-I (Figure 3-5E). Together these data support a model for filoviral 
immune evasion in which ZEBOV VP35 protein can potentially inhibit IFN production by 
sequestering viral RNA PAMPs from being recognized by RIG-I like receptors. 
 
3.5 ZEBOV VP35 dsRNA binding is correlated with IFN inhibition in vivo 
 
In order to assess the effect of these mutations on IFN inhibitory functions of VP35 in 
vivo, our collaborators used an IFN-β reporter assay, in which plasmids encoding either WT 
or mutant VP35 proteins were transfected into 293T cells, and monitored reporter activity 
induced by Sendai virus (SeV) infection (Figure 3-6). Our results suggest that the mutation of 
residues that abrogate RNA binding in vitro also diminish VP35’s role as an IFN antagonist 
in vivo. In the case of ZEBOV VP35, mutations such as R312A, K339A, K319A/R322A 
were able to attenuate VP35’s ability to inhibit SeV mediated IFN-β promoter activity, 
whereas mutation of residues in the FBP such as R222A, R225A, K248A and R251A do not 
have any effect on VP35 in this assay. This correlated well with IFN inhibition, as the same 
mutants that show diminished dsRNA binding also are impaired in inhbiting IFN-beta 
promoter activation in vivo. In addition to interacting the with dsRNA backbone, both 
ZEBOV and REBOV VP35 IIDs also interact with the blunt-ends of the dsRNA(Kimberlin 
et al, 2010; Leung et al, 2010). These are mediated through hydrophobic base-stacking  
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Figure 3-6. dsRNA binding and IFN inhibition are correlated.  
(A) IFN-beta reporter activation assays showing that mutation of FBP residues does not have 
any effect on IFN inhibition by ZEBOV VP35 IID. Mutation of CBP residues (C and D), and 
end-cap residues such as F239A (last lane in B) result in attenuated dsRNA binding in vitro 
and corresponding loss of IFN inhibition in vivo (Leung et al, 2010).  
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contacts mediated by residues such as F239, I340 and Q274in ZEBOV and F228, I340 and 
Q263 in REBOV. Given the importance of the basic residues of this protein in both immune 
evasion and viral replication, it was previously shown that deletions or mutations of VP35 
and its CBP residues resulted in attenuated growth of the virus in mice(Bray, 2001; Bray et 
al, 1999; Hartman et al, 2006). 
 
3.6 Mutation of CBP residues renders recombinant ZEBOV avirulent in 
guinea pigs 
 
Our collaborators extended our in vitro and cell-based assays by making recombinant 
ZEBOV virus carrying either the wildtype VP35 or the K319A/R322A mutation in VP35. In 
addition the GFP gene was engineered into the virus for monitoring the viral replication in 
cells. Using these viruses, our collaborators were able to show that both wildtype and the 
KRA virus were able to replicate efficiently in Vero cells, which lack IFN system (Figure 3-
7). In contrast only the WT virus was able to replicate in 293T cells, which can mount an IFN 
response to counteract the viral infection. The KRA virus was attenuated in 293T cells, 
highlighting the importance of dsRNA binding and IFN inhibition in the early stages of viral 
infection (Figure 3-7). Dr. Basler and colleagues were also able to show that the viral protein 
expression of the KRA virus was severely attenuated in 293T cells, whereas there was robust 
expression of viral proteins in the case of wildtype virus infection. Subsequently, our 
collaborators were able to show, using a guinea pig adapted virus, that ZEBOV virus 
carrying mutations in the central basic patch residues (K319A/R322A) was attenuated and  
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Figure 3-7. Replication of recombinant ZEBOV with CBP mutations is attenuated in 
293T cells.  
Recombinant ZEBOV virus containing wild type VP35 or VP35 containing K319A/R322A 
mutations were used to infect Vero cells (top two panels) or 293T cells (bottom two panels). 
Viral replication was visualized by monitoring expression of GFP which was engineered into 
the recombinant virus genomes (Prins et al, 2010). 
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Figure 3-8. Recombinant ZEBOV VP35 IID with CBP mutations is avirulent in guinea 
pigs.  
Recombinant ZEBOV with wild type (top) or K319A/R322A (bottom) containing VP35 
were used to infect guinea pigs and the animals were monitored by measuring body weight 
over a period of time. Animals infected by wildtype VP35 containing viruses die in 1 week 
post infection, whereas the CBP mutation containing virus was attenuated and the animals 
were able to grow past 2 weeks without symptoms and was able to protect the animals from 
further infection by wildtype virus (Prins et al, 2010).  
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animals infected with this virus showed no external symptoms and survived past two weeks, 
whereas animals infected with recombinant wildtype virus succumbed to infection in one 
week (Figure 3-8)(Prins et al, 2010). Moreover, the animals that had been infected with the 
mutant virus were completely protected when re-challenged with the wildtype virus, 
highlighting the importance of the dsRNA binding function and its role in early inhibition of 
innate immune responses in the context of viral infection (Figure 3-8). This experiment 
suggests that disruption of the dsRNA binding function of VP35 could be a potential strategy 
to develop therapeutics against filoviruses.  
 
3.7 Conclusions 
. 
Together this data supports a mechanism by which ZEBOV VP35 interferes with and 
prevents the recognition of viral RNA by RLRs and activation of the IFN-beta signaling 
pathway (Figure 3-9). The CBP residues, which make up the positively charged dsRNA 
binding surface of ZEBOV VP35 IID which includes R312, R322, and K339 play a critical 
role in IFN inhibition since alanine substitution of the CBP residues results in the loss of IFN 
inhibition in cell-based assays. In addition to the CBP, the coiled-coil region of VP35 (Figure 
2-3A), which facilitates VP35 oligomerization, is also important for the IFN antagonist 
function of VP35. This suggests that the oligomerization motif on the amino-terminus 
facilitates the IFN antagonist activity on the carboxy-terminus. More recently the crystal 
structure of REBOV VP35 IID-dsRNA complex was also solved. The structure suggested a 
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binding mechanism similar to that of ZEBOV VP35 IID. REBOV VP35 IID also forms a 
ligand-induced dimer mediated by conserved residues of the central basic patch. Similar to 
involvement of F239, Q274 and I340 in end-capping of dsRNA in the ZEBOV structure, the 
corresponding residues in REBOV VP35 IID F228, Q263 and I329 participate in end-
capping interactions with the blunt-ends of the dsRNA. 
In addition to the dsRNA-dependent inhibition mechanisms, VP35 can inhibit IFN 
pathway independent of dsRNA. For example, recent studies have shown that VP35 
transfection into 293T cells, affects the cellular localization of GFP-tagged IRF-3, causing it 
to be retained in the cytoplasm(Basler et al, 2003; Prins et al, 2009).  These studies also show 
that VP35 can also inhibit IFN-beta production by preventing IKK-ε and TBK-1 from 
phosphorylating their downstream substrates – IRF-3 and 7. In vitro studies established that 
VP35 can act as a pseudosubstrate for the IFN kinases, thus suppressing IFN-beta production 
using an RNA-independent mechanism downstream of RIG-I like receptors. When IRF3-5D, 
a constitutively active mutant of IRF-3 with phosphomimetic aspartate mutations, is used to 
stimulate IFN-beta production in 293T cells, EBOV VP35 is impaired in its ability to inhibit 
IFN-beta production, suggesting that it inhibits only the pathway upstream of IRF-3 
phosphorylation. In addition to the components of the IFN pathway, VP35 has also been 
reported to interact with a lot of other host proteins in order to evade host immune responses. 
For example, VP35 has been shown to inhibit the IFN induced gene PKR and prevent eIF2-
alpha phosphorylation(Feng et al, 2007; Schumann et al, 2009). In addition, VP35 has also 
been reported to inhibit RNA silencing by sequestration of dsRNA and direct interactions 
with the components of the RNAi machinery such as PACT and TRBP(Fabozzi et al, 2011; 
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Haasnoot et al, 2007). VP35 has also been reported to hijack the host SUMOylation 
machinery and target host proteins for degradation(Basler & Amarasinghe, 2009; Chang et 
al, 2009). Hence in addition to its role in viral replication and transcription, VP35 mediates 
immune evasion through multiple mechanisms and is a good target for therapeutic 
development against filoviruses. 
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Figure 3-9. Mechanisms of EBOV proteins inhibition of host immune responses. 
EBOV VP35 can bind to dsRNA and prevent activation of RIG-I like receptors. In addition 
VP35 can inhibit IRF-3 phosphorylation by acting as pseudo-substrate for the IFN kinases 
(Figure adapted from Ramanan et al, 2010). 
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CHAPTER 4. STRUCTURAL BASIS FOR MARBURG VIRUS 
VP35 MEDIATED IMMUNE EVASION MECHANISMS 
 
Ramanan P, Edwards MR, Shabman RS, Leung DW, Endlich-Frazier AC, Borek DM, 
Otwinowski Z, Liu G, Huh J, Basler CF, and Amarasinghe GK. Structural basis for 
Marburg virus VP35 mediated immune evasion mechanisms. Manuscript accepted for 
publication in Proceedings of the National Academy of Sciences of the United States of 
America. 
 
Structural and biochemical experiments were designed and implemented by me, with 
guidance from Dr. Gaya Amarasinghe and Dr. Daisy Leung. Initial identification of domain 
boundaries, cloning, expression, purification and identification of crystallization conditions 
for MARV VP35 IID, was performed by Dr. Daisy Leung. I subsequently optimized the 
construct space and identified new conditions to overcome diffraction related issues. In 
addition I identified conditions for crystallization of the MARV VP35 IID-dsRNA complex. 
I collected diffraction data at the Advanced Photon Source, beamline 19 ID with assistance 
from Dr. Gaya Amarasinghe, Dr. Daisy Leung and Dr. Dominika Borek. Dr. Zbysek 
Otwinowski, Dr. Dominika Borek, Dr. Daisy Leung and Dr. Gaya Amarasinghe provided 
insight and help in data processing, model building and refinement and validation of 
structure. I did the structural analysis and mutational studies based on structure, guided by 
Dr. Gaya Amarasinghe and Dr. Daisy Leung. Miss. Juyoung Huh cloned and expressed the 
RIG-I and MDA5 constructs used in the in vitro ATPase experiments. I performed 
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comparative RNA binding studies of MARV and ZEBOV VP35 with different RNA ligands. 
I performed ATPase assays with dsRNA and poly I:C to show inhibition of MDA5 and RIG-
I by MARV and ZEBOV VP35. Dr. Gai Liu and I performed in vitro RNA binding and 
ATPase experiments with overhang containing dsRNA, characterizing selective inhibition of 
dsRNA PAMPs by MARV VP35 IID. Dr. Christopher Basler, Dr. Reed S. Shabman, Megan 
Edwards and Ariel Endlich-Frazier designed, performed and analyzed all the in vivo 
experiments, characterizing IFN inhibition by MARV VP35 IID. I wrote the initial draft of 
the manuscript, except for the cell biological assays, which was written by Dr. Christopher 
Basler and colleagues at Mount Sinai School of Medicine. The final draft of the paper was 
submitted after editorial approval of all the authors. 
 
4.1 Introduction 
  MARV is one of the deadly filoviruses that cause hemorrhagic fever in humans(Gear 
et al, 1975; Towner et al, 2006). Many recent studies have shown that there are differences 
between MARV and EBOV not only at the genomic level but also at the level of viral protein 
structure and function(Enterlein et al, 2009; Muhlberger et al, 1998; Muhlberger et al, 1999; 
Sanchez et al, 1993; Valmas et al, 2010). Hence it is important to understand the similarities 
and differences between each of the viral proteins in EBOV and MARV in order to target 
common features for developing antivirals. In the case of EBOV, recent studies have shown 
that VP35 is a key protein involved in viral replication and immune antagonism and interacts 
with a range of different host proteins to mediate its immune antagonist function(Leung et al, 
2010a; Leung et al, 2010b; Prins et al, 2010a; Prins et al, 2009; Prins et al, 2010b; Schumann 
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et al, 2009). The availability of high-resolution structural information on EBOV VP35 IID, 
makes it an attractive therapeutic target, since it is well conserved across the different 
filoviral family members(Leung et al, 2009; Leung et al, 2010c). However, there is no such 
information available on MARV VP35 protein. Here we discuss our structural, biochemical 
and cell-based studies conducted on MARV VP35 IID in order to understand the 
mechanisms of immune evasion by MARV VP35 and compare and contrast it to EBOV 
VP35.  
 
4.2 Materials and methods 
Cloning, protein expression and purification. The coding region of MARV 
(Musoke strain) VP35 IID, full length RIG-I (residues 1-925), RIG-I ΔCARDs (residues 230-
925), full length MDA5 (residues 1-1025) and MDA5 ΔCARDs (residues 304-1025) was 
subcloned using Nde1 and BamH1 restriction enzyme sites into a modified pET15b 
expression vector, downstream of a MBP fusion tag and a TEV cleavage site. Using primers 
containing the desired mutations, mutant Zaire EBOV VP35 IID and MARV VP35 IID 
constructs were generated by overlap PCR, digested with restriction enzymes Nde1 and 
BamH1 and ligated into the same pET vector described above. PCR and DNA sequencing 
subsequently confirmed the presence of mutations. All the constructs mentioned above were 
expressed as MBP-fusion proteins by culturing transformed BL21(DE3) cells in LB media at 
37°C until an OD600 of 0.7. Cells were then chilled in ice and induced with 0.5mM IPTG and 
cultured overnight at 18°C. Cells were harvested by centrifugation at 10,000 g at 4°C for 10 
minutes. Harvested cells were resuspended in lysis buffer containing 25mM sodium 
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phosphate (pH 7.0), 1M NaCl, 5mM β-mercaptoethanol and a protease inhibitor cocktail, 
flash frozen using liquid nitrogen, and stored at -80°C. Cells were thawed and lysed using an 
Emulsiflex-C5 homogenizer (Avestin) and clarified by centrifugation at 30,000 g for 30 
minutes. The supernatant was then purified using a combination of affinity, cation exchange 
and size exclusion chromatographic columns (GE Healthcare). The MBP fusion tag was 
cleaved prior to final purification by using tobacco etch virus (TEV) protease. Protein purity 
was assessed by SDS-PAGE followed by Coomassie blue staining.   
 
Crystallization, data collection and processing. Crystallization trials were setup 
using purified MARV VP35 IID and 18bp dsRNA (Integrated DNA Technologies) mixed in 
2:1 molar ratio using hanging-drop vapor diffusion method at room temperature in standard 
24 well plates. Preliminary trials were performed using Hampton research kits and the 
resulting hits were optimized using in-house reagents. Single, three-dimensional rod-like 
crystals were obtained in well solution containing 0.1M ammonium citrate (pH 6.2), 0.1M 
ammonium citrate (pH 6.4), 0.25% ethylene glycol, 14% PEG 3350 and 0.23M ammonium 
sulfate. Crystals were cryoprotected by transferring them to well solutions containing 10% 
and 25% ethylene glycol for 10 seconds before plunge freezing in liquid nitrogen. Diffraction 
data was collected at the Advanced Photon Source (Beamline 19-ID). 440 frames of data 
were collected with a frame width of 0.5° and detector to crystal distance of 300 mm.  
 
Diffraction data were indexed, scaled and merged using HKL-3000. Intensities were 
converted to structure factors using CCP4 suite. Phase determination for MARV VP35 IID-
dsRNA complex was through molecular replacement by using chain B from wildtype 
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ZEBOV VP35 IID crystal structure (3FKE) as search model. Molecular replacement was 
performed using MOLREP in the CCP4 suite, and the resulting model was refined using 
REFMAC5. The resulting solution after molecular replacement provided a good model for 
the protein molecules in the structure. In order to model the dsRNA, an ideal A-form dsRNA 
helix was modeled and this model was manually built into the density for the dsRNA 
manually using Coot and merged with the protein model. Subsequent iterations of refinement 
and manual model building resulted in a satisfactory agreement between the model and 
experimental data for the structure as assessed by the final Rwork and Rfree values reported by 
REFMAC5 (Table 3-1). Water addition and manual model building was performed using 
Coot. TLS parameters were refined using the TLMSD server.  Final validation was 
performed using MOLPROBITY server.  
 
RNA binding studies. Isothermal titration calorimetry (ITC) assays to characterize 
protein-RNA interactions were performed using a VP-ITC (Microcal, North Hampton, MA). 
Protein samples for ITC studies were dialyzed overnight in a buffer containing 10mM 
HEPES pH 7.0, 150mM NaCl, 1mM MgCl2 and 2mM Tris(2-carboxyethyl)phosphine 
(TCEP) and the dialyzed buffer was used to make the dsRNA.  The raw data from VP-ITC 
was analyzed and processed using Origin software to obtain binding constants.  
For the double-membrane dot-blot assays, 125 picomoles of dsRNA was labeled 
with g-32P-ATP at 37°C for 1.5 hrs in a 50 µl reaction containing 1U/µl T4 polynucleotide 
kinase (New England Biolabs), 5µl 10X T4 PNK buffer and 50 µCi g-32P-ATP (Perkin 
Elmer). After 1.5 hours, 5 µl of sodium acetate (pH 5.4) and 125µl of ethanol were added and 
the RNA was precipitated at -20°C for 2 hours. Precipitated RNA was pelleted by 
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centrifugation for 30 minutes at 4°C and resuspended in 8M urea. The labeled RNAs were 
separated on a 7M urea, 15% acrylamide gel to separate out free nucleotides from RNA. 
RNA was identified and excised from gel by UV-shadowing and eluted into water with 5mM 
EDTA. Eluted RNA was ethanol precipitated again as described above, dissolved in water, 
separated into aliquots and stored at -20°C. RNA binding assays were carried out using a dot-
blot apparatus containing 96 wells. 50µL reactions, each containing varying protein 
concentrations in the range from 0 to 100µM and a constant 5nM g-32P-labeled dsRNA 
concentration were setup in a 96 well plate. The protein-RNA complex was then applied to 
each of the 96 wells in the dot-blot apparatus. Using vacuum pressure, the sample was passed 
through two sets of membranes - a nitrocellulose membrane (0.2 µm pore size, Biorad) 
assembled on top of a Zetaprobe nylon membrane (0.2 µm pore size, Biorad). Prior to and 
after sample application, the wells are washed twice with 500 µL binding buffer containing 
10mM HEPES (pH 7.0), 150mM NaCl, 2mM TCEP and 1mM MgCl2. The nylon and 
nitrocellulose membranes were air-dried and exposed to a phosphor screen (GE Healthcare) 
for 12-16 hours. Exposed screens were scanned using a Typhoon 9410 Variable Model 
Imager and quantified using ImageQuant software. Fractional binding was calculated as the 
ratio of the intensity of sample in nitrocellulose membrane to the sum of the intensities of 
nitrocellulose and nylon membranes. The resulting data were plotted using non-linear curve 
fitting function in Origin software to a one-site binding model to extract dissociation 
constants.  
 
ATPase assays. The ATPase activities of RIG-I and MDA5 constructs were monitored 
using thin layer chromatography (TLC) assay. Briefly, 50µL reactions were set up in a buffer 
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containing 10mM HEPES pH 7.0, 150mM NaCl, 1mM MgCl2 and 2mM TCEP, 100µM 
ATP, 5µCi g-32P-ATP and RIG-I or MDA5. 30bp dsRNA (IDT) or poly I:C (InvivoGen, San 
Diego, CA) were used as activators for RIG-I and MDA5 respectively, and wildtype or 
mutant VP35 IID proteins were added at various concentrations. Reactions were quenched 
with 50mM EDTA at desired time points and spotted on a 20cm by 10cm polyethyleneimine 
(PEI)-cellulose resin coated TLC plate (Baker-Flex, Germany) and placed in a TLC chamber 
containing 0.6M potassium phosphate monobasic pH 3.4 buffer The solvent front was 
allowed to migrate until it reached 1 cm below the top of the TLC plate, air-dried, saran-
wrapped and exposed to a phosphor screen (GE Healthcare) for 2-4 hours. Exposed screens 
were scanned using a Typhoon 9410 Variable Model Imager and quantified using 
ImageQuant software. ATPase activity for each lane was calculated by measuring the 
intensity of the inorganic phosphate. The resulting data were plotted using Origin software. 
 
4.3 Biochemical comparison of ebolavirus and marburgvirus C-terminal 
domain 
 
Filoviral VP35 protein is composed of an N-terminal oligomerization domain with 
putative coiled-coil regions(Moller et al, 2005; Reid et al, 2005), and a C-terminal interferon 
inhibitory domain (IID) (Leung et al, 2009). The C-terminal domain of VP35 is highly 
conserved among the different filoviruses, with about 90% similarity between the different 
species of EBOV and 57% similarity between ZEBOV and MARV (Figure 4-1). While some 
of the residues in the central basic patch such as R294, K298, R301 and K339 (corresponding 
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to residues R305, K309, R312 and K339 in ZEBOV VP35) are identical in both sequences, 
functionally important residues such as T308 and K311 (K319 and R322 in ZEBOV VP35) 
in the CBP and A214 and Y240 (R225 and K251 in ZEBOV VP35) in the FBP are not 
conserved. Guided by secondary structure analysis, sequence comparison with ZEBOV and 
REBOV VP35, we used an NMR-based domain mapping study to identifiy a C-terminal 
domain of MARV VP35, which would behave as an independently folded unit with solution 
properties that would make amenable for crystallography and biochemical characterization. 
We used heteronuclear single quantum correlation spectroscopy (HSQC) using uniformly 
15N-labeled protein. The HSQC experiment reports on the chemical shifts of the backbone 
amide group of each non-proline amino acid. These chemical shifts are exquisitely sensitive 
to the local chemical environment of the nuclei, which give rise to the NMR signal and hence 
report on the local secondary structure. While well folded proteins typically have unique 
well-dispersed chemical shifts with near uniform line widths and intensities, the amino acids 
present in disordered or unstructured regions of the protein give rise to chemical shifts that 
have markedly higher intensities and tend to show spectral crowding.  
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Figure 4-1. Multiple sequence alignment IID region of filoviral VP35 proteins.  
Sequence alignment of VP35 IID region of the different EBOV species, Bundibugyo 
(accession number ACI28621.1), Tai Forest (accession number ACI28630.1), Zaire 
(accession number AAD14582.1), Reston (accession number BAB69004.1), Sudan 
(accession number ABY75322.1) with MARV (accession number CAA78115.1). Conserved 
and identical residues are highlighted in black boxes, similar residues in gray boxes and non-
conserved residues in white boxes. The residue numbers indicated are for MARV VP35. The 
blue stars denote conserved basic residues belonging to the central basic patch. 
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Using this assay to guide our analysis, we were able to screen various N-terminal truncation 
constructs of MARV VP35 IID such as 166-329, 177-329, 182-329, 191-329 and 200-329. 
Extension of the N-terminus of the protein beyond residue 200 resulted in additional peaks at 
the center of the spectrum with markedly higher intensities relative to the rest of the spectrum 
(Figure 4-2), suggesting that these additional residues at the N-terminus are likely disordered 
in solution. Together, these data suggested that the construct comprising residues 200-329 
would be suitable for further biochemical and structural characterization of the C-terminal 
domain of MARV VP35 (Figure 4-2). Subsequent expression, purification and size 
chromatography analysis of the proteins suggested that these proteins could be obtained at 
high purity and homogeneity using bacterial expression systems.  
 
 
 
  
 
108 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. Identification of MARV VP35 IID domain boundary by NMR. 
1H- 15N heteronuclear single quantum coherence (HSQC) spectral overlay of MARV VP35 
IID constructs. Several N-terminal truncations of MARV VP35 IID (constructs indicated in 
blue, cyan, green, orange and pink) were tested for their solution properties. 
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We characterized the RNA binding characteristics of filoviral VP35 proteins using 
isothermal titration calorimetry and double-membrane filter binding assays. While ZEBOV 
VP35 is able to recognize and bind dsRNA ligands as small as 8 bp with a KD of 0.54 ± 0.08 
µM (Figure 4-3B), MARV VP35 preferentially binds longer dsRNA such as 18bp or 30bp 
(Figure 4-3C and D) with increasing affinity (KD of 6.55 ± 0.6 µM for 18bp dsRNA and KD 
of 1.31 ± 0.1 µM for 30bp dsRNA) and is completely incapable of binding 8 bp dsRNA 
(Figure 4-3A). In contrast ZEBOV VP35 IID binds to both 18bp and 30bp dsRNA with 
comparable affinities (KD of 2.19 ± 0.1 µM for 18bp dsRNA and KD of 2.24 ± 0.2 µM for 
30bp dsRNA). Given the sequence similarity in the C-terminal domain of VP35 among 
filoviruses, it was not immediately evident why there are differences in the RNA binding 
characteristics of ZEBOV and MARV VP35. In order to understand this, we used X-ray 
crystallography to determine the three-dimensional structure of these proteins in both the free 
form and bound to dsRNA. 
 
4.4 Structural studies of filoviral VP35 reveals distinct RNA binding modes  
Since the goal of my thesis is to understand the structural and functional similarities 
and differences between ZEBOV and MARV VP35, we determined the crystal structure of 
the C-terminal domain of MARV VP35 (residues 204-329) in complex with a palindromic 
sequence of 18bp blunt-ended dsRNA. Crystallization was done using a 2:1 molar 
concentration of protein to dsRNA and drops were set up using hanging-drop vapor diffusion 
method to obtain single diffraction quality crystals with dimensions of approx. 150µm in 
length, 35µm in width and 25µm thickness (Figure 4-4A). The crystals diffracted to 2.0Å  
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Figure 4-3. MARV VP35 IID binds to dsRNA in a length dependent manner.  
Isothermal titration calorimetry of MARV VP35 IID (A) and ZEBOV VP35 IID (B) with 8bp 
dsRNA. Binding curves from double-membrane dot-blot assay for 18bp (purple circles) and 
30bp (red triangles) dsRNA with MARV VP35 IID (C) and ZEBOV VP35 IID (D). Error 
bars represent s.d from two independent experiments. 
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resolution when exposed to a synchrotron radiation source (Figure 4-4B). We were able to 
obtain phases using one monomer of the ZEBOV VP35 IID structure (PDB: 3FKE) as the 
search model in molecular replacement (Figure 4-4C). We observed four molecules of 
MARV VP35 IID (chains A through D) and one 18bp dsRNA (chain E, F) in the 
crystallographic asymmetric unit (Figure 4-5A). Analysis of symmetry mates in the unit cell 
reveals an arrangement of molecules such that the dsRNA forms a pseudo-contiguous helix 
with a slight offset with the MARV VP35 IID molecules coating it along the backbone 
(Figure 4-5B). Notably, this is similar to the stoichiometry of 4 molecules of VP35 IID 
interacting with one molecule of dsRNA observed in the crystal structures of ZEBOV (PDB 
3L25 and 3L26) and REBOV VP35 IID (PDB 3KS8) bound to dsRNA. The absence of base-
specific contacts suggests that MARV interacts with dsRNA in a sequence independent 
fashion, similar to ZEBOV and REBOV VP35s. A number of conserved basic residues such 
as R294, K298, R301 and K328 form the positively charged protein surface that interacts 
through polar contacts with the negatively charged phosphodiester backbone of the RNA. 
The side chains of R294 and K298 interact with O1P of base U9, side chain of K328 and 
R301 interacts with the O2’ of C13 (Figure 4-6B). These residues are identical in REBOV 
(R294, K298, R301 and K328) and ZEBOV (R305, K309, R312 and K339) and are also 
involved in critical contacts with RNA backbone. As expected, structural alignment of 
EBOV and MARV VP35 IID shows that the overall fold, with the alpha helical and the beta 
sheet subdomains are well conserved and all of the secondary structural elements almost 
identical to each other. The backbone RMSD for the overall alignment is 0.82 Å for ZEBOV 
and 0.72 Å for REBOV (Figure 4-9A and B). Despite these striking similarities, there are 
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some notable differences in the basic residues that constitute the RNA binding interface, 
between MARV and ZEBOV.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4. Crystallization of MARV VP35 IID-dsRNA complex.  
(A) Representative crystals of MARV VP35 IID-18bp dsRNA complex obtained by hanging-
drop vapor diffusion method. (B) Representative diffraction pattern of the crystals, which 
diffracted to 2.0Å resolution at the synchrotron. (C) 2Fo-Fc density map at 1σ showing 
electron density (blue mesh) for both the RNA (red sticks) and the protein (yellow sticks). 
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Table 4-1. Statistics for data collection and refinement for MARV VP35 IID-dsRNA 
complex. 
 MARV VP35 IID-dsRNA complex 
Data collection  
Space group P212121 
Cell dimensions 
    a, b, c (Å) 
    α, β, γ (°) 
 
83.77, 93.38, 102.07 
90, 90, 90 
Resolution (Å) 50.00-2.01 (2.04-2.01)a 
Rsym or Rmerge (%) 9.4 (92.8) 
I/σI 22.9 (2.6) 
Completeness (%) 100.0 (100.0) 
Multiplicity of observation 
 8.7 (7.2) 
Refinement  
Resolution (Å) 37.87-2.02 (2.07-2.02) 
Number of reflections 45,910 (2577) 
Rwork/Rfree 18.7/24.0 
Completeness (%) 95.6 (48.6) 
Number of non-hydrogen atoms 5048 
B-factors 
     Protein 
 
 
 
 
     RNA 
 
 
     Water 
 
15.6 (chain A) 
16.2 (chain B) 
21.4 (chain C) 
15.3 (chain D) 
 
17.5 (chain E) 
19.5 (chain F) 
 
32.5 (chain W) 
R.m.s. deviations 
   Bond lengths (Å) 
   Bond angles (°) 
 
0.011 
1.496 
Ramachandran analysis 
   Favored (%) 
   Allowed (%) 
   Disallowed (%) 
 
99.8 
0.2 
0.0 
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While residues T308 and K311 are completely solvent exposed and play no part in RNA 
binding in MARV VP35, the equivalent residues in REBOV (K308 and R311) and ZEBOV 
VP35 (K319 and R322) are part of a critical network of polar contacts with RNA. Other 
notable differences include contacts mediated by residues such as N261 and Q263 with O3’ 
and O2’ of base U11 respectively (Figure 4-6A). The corresponding residues in REBOV 
(S261 and Q263) are also involved in polar contacts with RNA, but not in the case of 
ZEBOV (S272 and Q274).  
 
The most striking difference between dsRNA binding modes of MARV and EBOV 
VP35 IID is the absence of end-capping interactions (Figure 4-10A,B and C) Both the 
ZEBOV and REBOV VP35 IIDs interact with the blunt ends of dsRNA, through a series of 
hydrophobic contacts mediated through residues F239, I340 and Q274 in ZEBOV and F228, 
I329 and I267 in REBOV) (Figure 4-10D and E) (Kimberlin et al, 2010; Leung et al, 2010b). 
These end-capping interactions are facilitated through protein-protein interactions between 
VP35 IID molecules as observed in the crystal structures of both ZEBOV and REBOV VP35 
IID. The interface between VP35 IID molecules is formed through a network of hydrogen-
bonding interactions. The unique aspect of this interface is that the basic residues that are 
involved in RNA binding in one molecule of VP35 IID in the structure are involved in 
protein-protein interactions in the other molecule(Leung et al, 2010b). In the case of MARV 
VP35 IID, the conserved basic residues only interact with dsRNA and do not participate in 
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any intermolecular protein-protein interactions. In contrast, hydrogen-bonding interactions 
between side chain NH2 of R285 and backbone O atom of V280 and side chain OE1 of Q321  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-5. Crystal structure of MARV VP35 IID bound to 18bp dsRNA.  
(A) Four molecules of MARV VP35 IID, chains A(cyan), B(purple), C(green) and D(pink) 
bind only to phosphodiester backbone of one 18bp dsRNA (depicted in red as surface 
representation). (B) Symmetry related molecules showing the coaxial, end-to-end 
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arrangement of two dsRNA molecules in the unit cell with MARV VP35 IID molecules 
coating along the backbone (PDB 4GHL). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-6. Residues involved in dsRNA binding in MARV VP35 IID.  
(A) Side chains of residues R301, K328, R271, T267 and Q263 are engaged in hydrogen 
bonds with chain E of the dsRNA. (B) Residues such as K298, S299 and R294 form 
hydrogen bonds with chain F of dsRNA. Absence of base-specific contacts suggests a 
sequence independent binding mode to dsRNA. 
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Figure 4-7. Residues involved in protein-protein interactions in MARV VP35 IID.  
Side chains of residues R285, K287, N306 and Q321 are involved in hydrogen bond 
mediated protein-protein interactions with neighboring MARV VP35 IID monomers in the 
crystal structure.  
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and N and OD1 of N306 are observed between chains A and D and chains B and C in the 
asymmetric unit (Figure 4-7). These interactions are not as extensive as the protein-protein 
interactions observed in the case of Zaire and Reston EBOV(Kimberlin et al, 2010; Leung et 
al, 2010b) VP35 and may not be physiologically relevant in the case of MARV VP35 and 
may reflect crystal-packing contacts. In the case of MARV VP35, F228 (F239 in ZEBOV 
and F228 in REBOV) interacts with G12 base of dsRNA in contrast to its equivalent residues 
in ZEBOV and REBOV that pack against the blunt ends of the dsRNA (Figure 4-10F). In 
order to validate the importance of the residues that are observed in the crystal structure, we 
performed filter-binding assays of wildtype or mutant MARV VP35 IID constructs with 18bp 
and 30bp dsRNA (Figure 4-8). Consistent with the structure, mutation of residues involved in 
protein-dsRNA contacts resulted in diminished dsRNA binding, whereas mutation of 
residues involved in protein-protein interactions in the structure had no effect on dsRNA 
binding. 
 
In order to test whether the absence of end-capping interactions was indeed 
physiologically relevant and not an artifact of crystallization, we assessed the ability of 
ZEBOV VP35 and MARV VP35 to bind 25bp dsRNA containing blunt ends, 5’ overhang or 
3’ overhang using filter binding experiments. Our results show that while both ZEBOV and 
MARV VP35 are able to bind to blunt end dsRNA with similar affinities (KD of 1.32µM for 
MARV VP35 IID and KD of 2.14µM for ZEBOV VP35 IID), only MARV VP35 binds either 
5’ overhang or 3’ overhang containing dsRNA with affinities similar to blunt end dsRNA 
(KD of 1.69µM for 5’ overhang dsRNA and KD of 2.19µM for 3’ overhang dsRNA) (Figure 
4-11A). In contrast, EBOV VP35 binds to 5’ overhang and 3’ overhang containing dsRNA  
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Figure 4-8. Mutation of residues involved in mediating dsRNA contacts in structure 
also diminish dsRNA binding in vitro.  
Wildtype and mutant MARV VP35 IID proteins were assessed for their ability to bind 5'-end 
labeled (A) 18bp dsRNA and (B) 30bp dsRNA using double-membrane dot-blot 
experiments. Fractional binding of the mutants (gray bars) was normalized relative to 
wildtype protein (black bars). Error bars represent standard deviation from two independent 
experiments. 
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Figure 4-9. Overall fold of MARV VP35 IID is conserved and similar to EBOV.  
Structural alignment of MARV VP35 IID (yellow) bound to 18bp dsRNA (red) with ZEBOV 
VP35 IID (orange) bound to 8bp dsRNA (green) and REBOV VP35 IID (magenta) bound to 
18bp dsRNA (cyan) show that the overall fold containing the alpha helical and the beta sheet 
subdomains is conserved. 
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Figure 4-10. MARV VP35 IID does not bind dsRNA blunt ends unlike EBOV VP35 
IID.  
(A) MARV VP35 IID monomers (yellow) bind only to dsRNA backbone (yellow), whereas 
both (B) ZEBOV (orange) and (C) REBOV VP35 IID (magenta) bind to the respective 
dsRNAs (green and cyan respectively) as a dimer and contact both the blunt ends and the 
backbone. The F228 residue in (D) MARV VP35 IID contacts RNA base G12, which is in 
the middle of the dsRNA backbone, whereas the corresponding residues (E) F239 in ZEBOV 
VP35 IID and (F) F228 in REBOV VP35 IID end-cap the first base (C1 and U1 respectively) 
at the blunt-ends of the dsRNA.  
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Figure 4-11. MARV VP35 IID is insensitive to overhangs in dsRNA, unlike EBOV. 
Binding curves from dot blot assays for MARV VP35 IID (A) and ZEBOV VP35 IID (B) 
with 25bp blunt- end dsRNA (green squares), 25bp 5’overhang dsRNA (blue triangles) and 
25bp 3’ overhang dsRNA (orange inverted triangles). Error bars represent s.d. from two 
independent experiments.  
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with 3 and 15 fold lower affinity than blunt end dsRNA respectively (KD of 6.16µM for 5’ 
overhang dsRNA and KD of 30.12µM for 3’ overhang dsRNA) (Figure 4-11B). This data is 
consistent with our structures of ZEBOV VP35-dsRNA and MARV VP35-dsRNA 
complexes and suggests that MARV VP35, unlike ZEBOV VP35 does not recognize the 
dsRNA ends and binds only along the backbone. The dsRNA in the crystallographic unit cell 
is stacked coaxially in an end-to-end fashion forming a contiguous series of helices, coated 
by MARV VP35 IID molecules along its backbone, resembling beads on a string. This mode 
of RNA binding is unique and has not been observed with the EBOV VP35 proteins.  
 
4.5 Filoviral VP35 differentially inhibits RIG-I and MDA5 ATPase activity 
 
The absence of end-capping interactions and beads on a string model of RNA binding 
led us to hypothesize that our structure may have uncovered a novel mechanism MARV 
VP35 may employ as an immune evasion strategy, which is distinct from the mechanism we 
had proposed for ZEBOV VP35. This mode of binding may allow MARV VP35 to 
antagonize MDA5, the other key member of the RIG-I like receptor family of proteins 
involved in RNA sensing in the host cell. MDA5 has been long known to be activated by 
long dsRNA molecules including poly I:C and has been implicated in innate immune 
activation when host cells are infected by viruses with long RNA genomes(Kato et al, 2006). 
Recently, MDA5 has been shown to form filament-like structures by cooperative assembly 
on long dsRNA(Berke & Modis, 2012; Peisley et al, 2011).  
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Figure 4-12. MARV VP35 IID cannot inhibit dsRNA activation of RIG-I.  
The effect of 8 and 30 bp dsRNA and VP35 on ATPase activities of RIG-I and MDA5 were 
assessed by TLC. (A) 8 bp dsRNA and (C) 30bp dsRNA were used to activate RIG-I ATPase 
activity (lane 3). Zaire EBOV VP35 IID (lanes 4-7 in A and lanes 4-8 in C) and MARV 
VP35 IID (lanes 8-11 in A and lanes 9-13 in C) were tested for their abilities to inhibit RIG-I 
ATPase activity by these dsRNAs. The free inorganic phosphate in each lane (figure A and 
C) was quantified, normalized to lane 3 and plotted as normalized ATPase activity in figures 
B and D. Error bars represent standard deviation from two separate experiments.  
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MARV VP35 may be able to effectively compete with MDA5 and prevent such filament 
assembly, thus inhibiting important signaling events through MDA5 resulting in inhibition of 
IFN production. Because MARV VP35 does not bind short dsRNA ligands and cannot 
recognize the RNA ends, we hypothesize that MARV VP35 likely does not inhibit dsRNA 
mediated RIG-I activation. We have previously shown that ZEBOV VP35 interacts with the 
dsRNA backbone as well as the ends mimic the host receptor RIG-I’s binding mode to 
dsRNA. Our structural and biochemical evidence suggests that MARV VP35 binds dsRNA 
in a manner that resembles MDA5 recognition of long dsRNA and poly I:C. This led us to 
hypothesize that MARV VP35 may be able to inhibit MDA5 activation and innate immune 
signaling by poly I:C. In order to test this hypothesis, we used thin layer chromatography 
assays to assess the ATPase activity of RIG-I and MDA5 proteins in the presence of 
activating ligands such as dsRNA and poly I:C. Our findings show that RIG-I ATPase 
activity is strongly activated by dsRNA, and this dsRNA mediated activation can be inhibited 
by ZEBOV VP35 IID in a dose dependent manner. In contrast, MARV VP35 IID is unable to 
inhibit dsRNA mediated RIG-I ATPase activity, which is consistent with our structural and 
biochemical data. Because MARV VP35 does not bind the blunt ends of the dsRNA, it is 
unable to compete with RIG-I, and hence unable to inhibit the ATPase activity. On the other 
hand, ZEBOV VP35 is able to outcompete RIG-I for dsRNA binding and thus inhibit 
ATPase activity. We tested the ATPase activity of MDA5 using the same assay. Consistent 
with previous findings, our studies show that poly I:C is able to activate the ATPase activity 
of MDA5. In contrast to RIG-I, both ZEBOV and MARV VP35 can inhibit poly I:C 
mediated activation of MDA5, validating our structural and biochemical data.  
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Figure 4-13. MARV VP35 is able to inhibit activation of MDA5 by poly I:C. 
(A) ATPase activity of MDA5 was assessed by TLC using low-molecular weight (LMW) 
(lane 2) and high-molecular weight (HMW) (lane 5). Both Zaire EBOV VP35 IID (lanes 3 
and 6) and MARV VP35 IID (lanes 4 and 7) were tested for their abilities to inhibit RIG-I 
ATPase activity by poly I:C. MARV VP35 IID mutants such as R924A/K298A (lane 11), 
F228A (lane 12),K287A (lane 13), and N306A (lane 14) were tested for their abilities to 
inhibit MDA5 activation by poly I:C. The quantitated ATPase activity, normalized to lane 2 
is plotted in F. (B) The free inorganic phosphate in each lane was quantified, normalized to 
RIG-I activation by LMW poly I:C (lanes 2 and 9) and plotted as normalized ATPase 
activity. Error bars represent standard deviation from two separate experiments. 
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These results show that the mode of dsRNA binding by the filoviral VP35 proteins may play 
a role in differentially inhibition of the RIG-I like receptors. Together our data support a 
model in which ZEBOV and MARV VP35inhibit the production of type I IFN by hiding 
viral RNA from being recognized by these critical host pattern recognition receptors. 
4.6 Disruption of VP35-dsRNA interactions in vitro results in attenuated 
IFN inhibition in vivo 
 
We carried out filter binding assays to assess the RNA binding ability of wildtype and 
mutant MARV VP35 IID proteins. While WT MARV VP35 IID binds dsRNA with high 
affinity, filter binding data shows that alanine substitution of basic residues R301, K328, 
R294, K298 and S299 all resulted in diminished RNA binding (Figure 4-8), consistent with 
the interactions observed in the structure. Double mutations of residues R294/K298 and 
K298/S299 to alanine completely abolished dsRNA binding, suggesting a critical role for 
these residues (Figure 4-8). In addition, mutation of residues F228. N261 and Q263 to 
alanine, also resulted in diminished RNA binding. Poly I:C pulldowns of WT and mutant 
MARV VP35 proteins which were consistent with the filter binding assays and corroborated 
the role of these residues in dsRNA binding as observed in the structure.  
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Figure 4-14.  Mutations of residues involved in dsRNA binding in MARV VP35 IID 
attenuate IFN- β inhibition and IRF-3 phosphorylation.  
(A) and (B) The IFN-β promoter activity induced by SeV infection of 293T cells transfected 
with either WT or mutant MARV VP35 proteins (black bars) were normalized relative to the 
empty vector control (gray bars). Error bars represent standard error of the mean for triplicate 
experiments. (C) Western blot analysis of the IRF3 phosphorylation state in 293T cells after 
SeV activation of the IFN-β promoter using anti-phospho IRF3 (top panel) and anti-IRF3 
(middle panel) antibodies. The bottom panel is the expression of the different MARV VP35 
mutants using monoclonal anti-MARV VP35 IID antibody. MARV NP was used as a 
negative control. E refers to empty vector transfection control. The * indicates a non-specific 
band. 
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In contrast, alanine substitutions of residues such as R285, K287, N306 and Q321 which are 
involved in protein-protein interactions in the crystal structure, did not have an impact on 
RNA binding in both the filter binding as well as the poly I:C pull-downexperiments (Figure 
4-8), suggesting that these contacts are more likely formed in the context of crystal packing. 
 
Previous studies with ZEBOV VP35 have shown that one of the key mechanisms 
underlying ZEBOV’s ability to suppress IFN-β production is through inhibition of IRF-3 and 
IRF-7 phosphorylation by the IFN kinases IKK-ε and TBK-1. In order to test whether 
MARV VP35 employs a similar strategy, our collaborators tested the phosphorylation states 
of IRF-3 in 293T cells upon SeV activation. Similar to ZEBOV, MARV VP35 also inhibits 
IRF-3 phosphorylation. Mutations that result in loss of dsRNA binding also result in 
diminished ability to inhibit IRF-3 phosphorylation. In addition, MARV VP35 is also able to 
block IFN-β promoter activity upon overexpression of IKK-ε or TBK-1 in 293T cells. In 
contrast, when IRF-3 5D, a constitutively active form of IRF-3, is overexpressed in 293T 
cells, MARV VP35 is unable to inhibit the IFN-β promoter activity, suggesting that the 
inhibitory effect of MARV VP35 is upstream of IRF-3 phosphorylation and activation.  
 
In order to assess the effect of these mutations on IFN inhibitory functions of VP35 in 
vivo, our collaborators used an IFN-β reporter assay, in which we transfected plasmids 
encoding either WT or mutant VP35 proteins into 293T cells, and monitored reporter activity 
induced by Sendai virus (SeV) infection. These results suggest that the mutation of residues 
that abrogate RNA binding in vitro also diminish VP35’s role as an IFN antagonist in vivo.  
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Figure 4-15.  RNA-independent mechanism of immune evasion by MARV VP35.   
IFN-β promoter activity of WT or mutant MARV VP35 proteins in 293T cells induced by 
overexpression of (A) FLAG-IKKe, (B) FLAG-TBK-1 or (C) constitutively active IRF3-5D 
constructs. The promoter activity was normalized to the empty vector control denoted as E. 
Error bars represent standard error of the mean for triplicate experiments. Western blot 
analysis of the protein expression levels were detected using anti-FLAG M2, anti-IRF3 and 
anti-MARV VP35 IID antibodies. Endogenous IRF-3 can be distinguished from IRF3-5D by 
the difference in migration on SDS gels (indicated by lines on lower panel of C). 
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In the case of  ZEBOV VP35, mutations such as R312A, K339A, K319A/R322A were able 
to attenuate VP35’s ability to inhibit SeV mediated IFN-β promoter activity, whereas 
mutation of residues in the FBP such as R222A, R225A, K248A and R251A do not have any 
effect on VP35 in this assay.  
 
In the case of MARV VP35, the double-mutants R294A/K298A, K298A/S299A and 
N261/Q263 completely suppress VP35’s ability to suppress IFN-β activation, followed by 
the point mutants R301A, K298A, K328A, S299A and F228A, which also show diminished 
IFN-β suppression relative to WT protein. In contrast R285A, K287A, N306A and Q321A 
mutants performed as well as WT in this assay, suggesting a strong correlation between 
dsRNA binding and IFN inhibitory functions of VP35.  
 
4.7 Conclusions 
	     
Here we provide data to support a model that suggests that the dsRNA-binding mode 
of filoviral VP35 has a direct impact on its ability to antagonize the RIG-I like receptors. 
Using the ATPase activity of RIG-I and MDA5 (estimated by thin-layer chromatography) as 
an indicator of the functionally active state of the molecules, we tested the effect of both 
ZEBOV and MARV VP35 on RIG-I and MDA5. Our data show that short dsRNA is able to 
activate ATPase activity of RIG-I, while poly I:C activates MDA5. Only ZEBOV VP35 is 
able to inhibit dsRNA-mediated ATPase activity in a dose-dependent manner while MARV 
VP35 cannot. We show that this is directly correlated to the ability of ZEBOV VP35 to 
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compete with RIG-I for binding dsRNA backbone and blunt ends, because mutation of 
residues such as R312, F239, K319 and R322 abrogates ZEBOV VP35’s ability to inhibit 
RIG-I. MARV VP35 does not interact with blunt ends of dsRNA; it is unable to inhibit RIG-I 
in this assay. In contrast, both MARV and ZEBOV VP35 can inhibit poly I:C mediated 
activation of MDA5, suggesting that while MARV cannot compete with RIG-I for dsRNA 
binding, it is able to compete with MDA5 (Table 4-2). This may be a key difference between 
the dsRNA-dependent immune evasion strategies employed by ZEBOV and MARV VP35. 
Our data provides a structural and functional basis for the observed lack of binding to short 
dsRNA binding by MARV VP35 and its inability to distinguish between blunt end and 
overhang containing dsRNA (Figure 4-16). It is interesting to note that although ZEBOV and 
MARV may exhibit the said differences in dsRNA-dependent mechanism of immune 
evasion, both proteins are able to inhibit the type I IFN pathway using a common RNA-
independent mechanism by inhibiting TBK-1 and IKK-ε mediated phosphorylation of IRF-
3/7 (Figure 4-16). This is another example of the structural plasticity of VP35 where the 
same fold results in distinct RNA binding modes but may mediate similar protein-protein 
interactions with the IFN kinases. Taken together our data have identified some potential 
differences and similarities in the immune evasion strategies of ZEBOV and MARV VP35. 
Further investigation is needed to evaluate the impact of these differences on pathogenesis 
and disease outcome. The identification of common and distinct structural features of 
filoviral immune antagonists is key for the rational design of therapeutics that can target both 
EBOV and MARV.   	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Table 4-2. Biochemical and structural differences between MARV and EBOV VP35 
proteins, which are important for immune evasion mechanisms. 
 
 
EBOV VP35 IID-dsRNA 
complex 
MARV VP35 IID-dsRNA 
complex 
STRUCUTAL DIFFERENCES  
Central basic patch residues such as 
R312, K319 and R322 are involved in 
dsRNA binding and protein-protein 
interactions 
Central basic patch residues 
involved only in protein-dsRNA 
interactions. Protein-protein interactions 
are through distinct residues such as R285, 
K287, N306 and Q321. 
Residues K319 and R322 in CBP 
are very important for both dsRNA binding 
and protein-protein interactions 
Corresponding residues T308 and 
K311 are solvent exposed and don’t make 
any contacts 
F239, I340 and Q274 are involved 
in dsRNA end-capping interactions 
Corresponding residues F228, I329 
and Q263 are involved in dsRNA 
backbone contacts 
BIOCHEMICAL DIFFERNCES  
Binds 8bp dsRNA. Does not bind 8 bp dsRNA.  
Binds to 18bp and 30bp dsRNA 
with similar affinities 
Binds 30bp dsRNA with 3-fold 
higher affinity than 18bp dsRNA 
Binds blunt-end dsRNA with 3-fold 
and 15-fold higher affinity than 5’ and 3’ 
overhang dsRNA 
Binds blunt-end, 5’overhang and 3’ 
overhang containing dsRNA with similar 
affinites 
Can inhibit RIG-I ATPase 
activation by 8 and 30bp dsRNA by 
binding to blunt-end PAMPs 
Cannot inhibit RIG-I ATPase 
activation by 8 and 30bp dsRNA since it 
cannot bind to blunt-end PAMPs 
Can inhibit RIG-I ATPase 
activation by 5’ and 3’ overhang containing 
dsRNA by binding to dsRNA PAMPS 
Can inhibit RIG-I ATPase 
activation by 5’ and 3’ overhang 
containing dsRNA by binding to dsRNA 
PAMPS 
Can inhibit MDA5 ATPase 
activation by polyI:C, by binding to dsRNA 
PAMPs 
Can inhibit MDA5 ATPase 
activation by polyI:C, by binding to 
dsRNA PAMPs 
Inhibits IRF-3 phosphorylation by 
directly interacting with IKK-e and TBK-1 
through CBP residues 
Inhibits IRF-3 phosphorylation by 
unknown mechanism mediated by different 
set of residues from CBP. 
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Figure 4-16.  Model for filoviral VP35 mediated immune evasion.   
Both ZEBOV and MARV VP35 inhibit recognition of double-strandedness PAMP by RIG-I 
like receptors by sequestration of RNA ligands. In contrast, only ZEBOV VP35 can inhibit 
blunt-end PAMP recognition by RIG-I like receptors. Both ZEBOV and MARV VP35 can 
inhibit type I IFN production in RNA-independent mechanism by inhibiting the IFN kinases 
from phosphorylation of downstream IRF-3/7 transcription factors. 
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CHAPTER 5. CONCLUSIONS 
 
Viruses are obligate parasites and are completely dependent on host cells for viral 
protein production and replication. A multitude of factors determine the outcome of viral 
infection. One of the important factors is the ability of the host cell to mount an effective and 
potent innate immune response, which is the first line of defense against any pathogen. 
Viruses encode proteins that hijack host cell machinery and reprogram cellular pathways to 
aid viral replication. To do this, viruses must first escape detection by the specialized proteins 
in the host cell, whose specific function is to detect and counter viruses and other pathogens. 
Viral proteins achieve this by multiple mechanisms that target various components of the 
host immune responses. Viral replication occurs at an extremely rapid pace compared to 
hosts, and viral polymerases are highly prone to errors during viral genome replication. The 
high frequency of mutations confers a probabilistic advantage in adapting to host immune 
defenses. Given this rapid rate of replication and mutation, viral proteins are more likely to 
sample beneficial mutations that allow it to evade host immune responses. Hence studying 
host-virus interactions is a challenging and interesting area of research due to the dynamic 
nature of the processes involved, in which viral components constantly evolve strategies to 
subvert the host defense mechanisms in order to successfully replicate, while immune 
components of host constantly adapt to the new challenges posed by pathogens in order to 
ensure the survival of the host and clear the virus.  
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Filoviruses are among the deadliest viruses that cause severe disease in humans, and 
currently there are no approved treatments for filoviral infections. The severe pathogenesis 
associated with filoviral infections has been attributed to the early and effective shut down of 
host innate immune responses, which also results in impaired adaptive immune responses. 
The fact that filoviruses encodes only seven proteins, which perform multiple functions can 
be taken advantage of, because it allows us to focus our attention on a few critical proteins 
that the virus is absolutely dependent on for survival in host cells. High-resolution structural 
information of viral proteins is absolutely critical for understanding the role of specific 
residues in immune evasion and other functions that aid viral replication. These studies can 
contribute to our fundamental understanding of protein structure and function, specifically 
how one protein fold has evolved to perform multiple, completely unrelated functions. This 
can be attributed to the plasticity of the protein structure and the conformational ensembles it 
can sample over time and space, based on the effect of external factors such as temperature, 
pH, ligands such as small molecules, other proteins and nucleic acids. Among the filoviral 
proteins that function as immune antagonists, VP35 is one of the key virulence factors that 
have been shown to inhibit host innate immune responses through its interactions with 
dsRNA and a variety of host proteins. Additionally VP35 plays a role as a structural protein 
and a co-factor in the viral polymerase complex. Recent studies focused on understanding 
VP35 mediated immune evasion have been predominantly done using EBOV VP35. Prior to 
this study, there was limited structural, biochemical or cell biological data showing the 
functions of MARV VP35. 
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In this study, we provide evidence to support a novel mechanism by which MARV 
VP35 protein mediates suppression of the host innate immune responses. We provide 
structural and biochemical evidence to highlight the differences between EBOV and MARV 
VP35 in their dsRNA binding characteristics. First, we show that MARV VP35 binds to 
dsRNA in a length dependent manner. Second, we show that MARV VP35 does not 
recognize the blunt-ends of dsRNA, unlike EBOV VP35. Using enzymatic assays, we show 
that MARV VP35 cannot prevent the dsRNA-mediated activation of RIG-I, the host receptor 
that recognizes both the double-strandedness and the blunt-end features of RNA. In contrast, 
MARV VP35 is able to inhibit poly I:C mediated activation of MDA5, another host receptor 
that recognizes only the double-strandedness of RNA. In contrast EBOV VP35 can inhibit 
both RIG-I and MDA5 due to its ability to bind both blunt-ends and double-stranded regions 
of RNA. Although the molecular details leading to the differences observed in the RNA 
binding characteristics of MARV and EBOV VP35 are still not completely understood, our 
work has identified differences in amino acids at key positions involved in both protein-
protein and protein-dsRNA interactions that likely contribute to these differences. In addition 
to the RNA-dependent mechanism, we also provide evidence showing that both MARV and 
EBOV VP35 can also inhibit host innate immune responses using an RNA-independent 
mechanism, by inhibiting IRF-3 phosphorylation by the IFN kinases IKK-ε and TBK-1. In 
summary this work not only provides an additional structural target for development of 
antiviral therapies, but also gives new insights into the differences and similarities in 
mechanisms of MARV and EBOV VP35 mediated immune evasion. 
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